Psychological problems among cancer patients in relation to healthcare and societal costs: A systematic review

Florie E. Van Beek | Lonneke M. A. Wijnhoven | Karen Holtmaat | José A. E. Custers | Judith B. Prins | Irma M. Verdonck-de Leeuw | Femke Jansen

Department of Clinical, Neuro- and Developmental Psychology, Faculty of Behavioral and Movement Sciences, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Department of Medical Psychology, Radboudumc Nijmegen, Radboud Institute of Health Sciences, Nijmegen, The Netherlands

Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, VUmc Cancer Center Amsterdam, Amsterdam, The Netherlands

Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands

Correspondence
Femke Jansen, Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
Email: f.jansen1@amsterdamumc.nl

Funding information
ZonMw, Grant/Award Number: 856001005

Abstract

Objective: This study systematically reviewed the association of psychological problems among cancer patients with healthcare and societal resource use and costs.

Methods: PubMed, PsycINFO, and Embase were searched (until 31 January 2021) for studies on psychological symptoms (anxiety, depression, distress, fear of recurrence) or psychiatric disorders (anxiety, depression, adjustment) and healthcare use (e.g., mental, inpatient healthcare), economic losses by patients and family, economic losses in other sectors (e.g., absence from work), and costs. The search, data extraction, and quality assessment were performed by two authors.

Results: Of the 4157 identified records, 49 articles were included (psychological symptoms (n = 34), psychiatric disorders (n = 14), both (n = 1)) which focused on healthcare use (n = 36), economic losses by patients and family (n = 5), economic losses in other sectors (n = 8) and/or costs (n = 13). In total, for 12 of the 94 associations strong evidence was found. Psychological symptoms and psychiatric disorders were positively associated with increased healthcare use (mental, primary, inpatient, outpatient), losses in other sectors (absence from work), and costs (inpatient, outpatient, total healthcare costs). Moderate evidence was found for a positive association between (any) psychiatric disorder and depression disorder with inpatient healthcare and medication use, respectively.

Conclusions: Psychological problems in cancer patients are associated with increased healthcare use, healthcare costs and economic losses. Further research is needed on psychological problems in relation to understudied healthcare use or costs categories, productivity losses, and informal care costs.

Keywords
cancer, costs, healthcare use, oncology, psychiatric disorder, psychological symptom, work productivity
1 | BACKGROUND

Psychological problems such as symptoms of anxiety, symptoms of depression, psychological distress and fear of cancer recurrence are commonly reported in cancer patients.1–3 In case of severe problems a psychiatric disorder may be present. Approximately 11–19% of all cancer patients have a major depression disorder, anxiety disorder or adjustment disorder.4 These psychological problems may, besides influencing a patients’ health-related quality of life,5 also have economic consequences.6

As previously hypothesized by Carlson and Bultz,6 cancer patients with psychological problems may not only have increased mental healthcare use, they may also make more use of other domains of healthcare such as general practitioner (GP) visits or hospitalization. Patients with psychological problems are less likely to adhere to cancer treatment or lifestyle recommendations, which may affect their treatment effectiveness and in turn may increase healthcare use.7 Also, cancer patients with psychological problems are at higher risk of developing comorbidities (e.g., diabetes and cardiovascular disease),8,9 which may result in higher healthcare use. Besides higher healthcare use, psychological problems may also impact on economic losses by patients and their family themselves (e.g., out of pocket purchases or received informal care)9 and economic losses in other sectors for example productivity losses due to absence from work (i.e., sick leave) or decreased work productivity.10,11 Psychological problems among cancer patients are thus hypothesized to result in high economic costs from both a healthcare and societal perspective.

It is important to gain detailed insight into these economic consequences of psychological problems among cancer patients, as healthcare costs and other societal costs of cancer are already high,12 and decisions have to be made on allocation of limited healthcare resources. Recently a systematic review (2018)13 on 10 studies up to December 2017 investigated the relation between psychiatric disorders and healthcare costs among cancer patients. This systematic review revealed that psychiatric disorders are associated with increased healthcare use and costs across all phases of the cancer trajectory. This systematic review was, however, limited to studies from the United States and did not include studies on psychological symptoms or studies that investigated economic losses of patients, their family or other sectors (e.g., productivity losses). In addition, two systematic reviews investigated factors associated with return to work after cancer diagnosis among cancer patients.14,15 However these two reviews did not specifically focus on the economic consequences of the association between psychological problems and return-to-work (i.e., the actual time absent from work).

No systematic review has, so far, focused on the association between psychological problems (including both psychological symptoms and psychiatric disorders) and all potentially related healthcare and societal resource use and costs among cancer patients. Therefore, the aim of this study was to systematically review associations between psychological problems (anxiety, depression, fear of cancer recurrence, distress, adjustment to cancer) and healthcare and societal related resource use and costs among cancer patients. Results are relevant both from the perspective of cancer patients and their families, as well as their employers (productivity), and the healthcare system with respect to reimbursement of psychological treatment for cancer patients.

2 | METHODS

2.1 | Literature search

Preferred reporting items for systematic reviews and meta-analyses guidelines were used to conduct and describe this systematic review.16 A comprehensive search was conducted in PubMed, Embase, and PsycINFO from inception up to 31 January 2021. Our search strategy included combinations of keywords, MeSH terms and synonyms which were adapted for each database search, related to three main topics: (1) cancer patients, (2) psychological problems (i.e., psychological symptoms including anxiety symptoms, depressive symptoms, distress and fear of cancer recurrence and psychiatric disorders including anxiety disorder, depression disorder and adjustment disorder) and (3) the use or costs of healthcare or societal resources (e.g., visits to the GP, medication use, inpatient costs, informal care costs, productivity losses).

A detailed description of the search strategy is available in Appendix 1. An information specialist from the medical library provided advice on the literature search. Additionally, reference lists from included articles were manually searched and authors were asked for additional studies.

2.2 | Study inclusion and exclusion criteria

Research studies were included if:

(1) they investigated the association between psychological symptoms (i.e., symptoms of anxiety or depression, distress, or fear of cancer recurrence) or a psychiatric disorder (i.e., anxiety disorder, depression disorder or adjustment disorder) and the use or costs of healthcare or societal resources;
(2) they included adult cancer patients (age ≥ 18 years) only; and
(3) full text was available in English or Dutch.

Research studies were excluded if they:

(1) presented descriptive statistics on the use or costs of healthcare or societal resources in a certain cancer population without investigating its association with (level of) psychological problems;
(2) measured work ability or work performance instead of lost working hours;
(3) measured return-to-work (yes/no) without insight on time absent from work;
(4) measured return-to-work among cancer patients who were not of working age (i.e., included both patients of working age and those who were retired) or
(5) were reviews

No limits were set for year of publication.

2.3 | Selection process and quality assessment

After removing duplicates, two independent reviewers (F. E. Van Beek and L. M. A. Wijnhoven) screened all identified records based on title and abstract. Records that were not relevant based on the screening were excluded. Subsequently, the full-text article of potentially relevant records were screened for eligibility using the inclusion and exclusion criteria. In case of disagreement, the full-text article was discussed by the two reviewers, and when needed a third author (F. Jansen) was involved to meet consensus.

The quality of the included study was assessed with an 11-item quality assessment scoring list based on Hayden et al.\textsuperscript{17} and Drummond et al.\textsuperscript{18,19} This list compromises four domains: study population, study attrition, data collection and data analysis. Each item was scored positive (“1”) or negative (“0”). In case information to evaluate an item was lacking, that item was scored negative as well. In case an item was not applicable, that item was scored as “not applicable (N/A).” A total score was calculated by summing the item scores, resulting in a score ranging from 0 (lowest quality) to 11 (highest quality). The quality assessment was conducted independently by two reviewers (F. E. Van Beek and L. M. A. Wijnhoven). In case of disagreement, the item was discussed by the two reviewers, and when needed a third author (F. Jansen) to meet consensus. In line with previous studies,\textsuperscript{20,21} the article was rated “high quality” when an article was assigned at least 70% of the total score.

2.4 | Data extraction

All studies eligible for inclusion were read thoroughly to extract data. For the data extraction a standardized collection form was used including: general information (first author, publication year, country), study design, study population (number of patients included, cancer site, relevant inclusion and exclusion criteria), psychological outcome and its measurement, use/costs outcomes and its measurement, and results (e.g., odds ratio, risk ratio, differences in mean). Based on the Dutch cost guideline of the National Healthcare Institute,\textsuperscript{22} the use/cost outcome were, categorized into (1) healthcare use (e.g., medical specialist visits, length of hospital stay, medication use), (2) economic losses by patients and family (e.g., time expenses for providing informal care, travel costs, out of pocket payments) and (3) economic losses in other sectors (e.g., absenteeism from work). In addition, a fourth category was added in which healthcare use, losses by patients and family, and/or losses in other sectors were valued in monetary units. Based on the associations found in the literature, the four categories were further divided into subcategories including healthcare use (i.e., mental healthcare, supportive nonmental healthcare, primary care, oncology-related healthcare, inpatient care, outpatient care, medication, and other healthcare use), economic losses by patient and family (i.e., complementary and alternatively medicine use (CAM), healthcare use of spouses, and lost work productivity of spouses), economic losses in other sectors (i.e., return-to-

| 1. Healthcare use* |
|------------------|
| • Mental healthcare |
| • Supportive non-mental healthcare |
| • Primary care |
| • Oncology-related healthcare |
| • Inpatient care |
| • Outpatient care |
| • Medication |
| • Other healthcare use |

| 2. Economic losses by patient and family |
|----------------------------------------|
| • complementary and alternatively medicine use |
| • Healthcare use of spouses |
| • Lost work productivity of spouses |

| 3. Economic losses in other sectors |
|----------------------------------|
| • Return to work |

| 4. Healthcare use, losses by patients and family and losses in other sectors measured in monetary units |
|------------------------------------------------------------------------------------------------|
| • Mental healthcare |
| • Inpatient |
| • Outpatient |
| • Medication |
| • Total healthcare |
| • Absenteeism and presenteeism (costs) |
| • Out of pocket costs |
| • Other costs |

\textbf{FIGURE 1} Categorization of healthcare and societal resource use and costs. *For the subcategorization, we were dependent on the description provided in the individual studies. Healthcare resource utilization was only categorized in the subcategory “oncology-related healthcare” if this matched the definition used in the corresponding article. In all the other cases, the investigated association was categorized in a broader subcategory, for example, “outpatient care”
work) and losses in monetary units (i.e., mental healthcare, inpatient, outpatient, medication, total healthcare, absenteeism and presentisms (costs), out of pocket costs, and other costs) (Figure 1).

2.5 | Statistical methods and level of scientific evidence

We used a best-evidence synthesis to estimate the level of evidence for the investigated associations between psychological problems and healthcare use, economic losses by patients and family, economic losses in other sectors, and total costs, as used in previous studies.20,21,23 The levels of evidence were (1) strong if an association was consistently supported by at least two high quality studies, (2) moderate if an association was consistently supported by at least one high-quality study and at least one low-quality study or if a factor was consistently supported by at least two low-quality studies, and (3) inconclusive, if an association was supported by only one study, results were inconsistent or did not show an indication for a positive or negative association.

3 | RESULTS

3.1 | Identification and selection of studies

In total 4157 articles were yielded by PubMed, Embase and Psy- cINFO. Of these studies 272 were selected for full text review (Figure 2). In total 49 studies24-71 fulfilled the eligibility criteria and were included in this systematic review. The majority of the studies focused on healthcare use (n = 36)24,25,27-30,33-35,37-39,41-48, 51,53,54,56-62,64,67,69-72 followed by studies on costs in monetary units (n = 13),26,29,34,36,38,42-44,48,53,55,57,61 economic losses in other sectors (n = 8)30,32,34,36,38,42-44, 48,53,57,61,69 and economic losses by patients and family (n = 6).28,29,50,52,64,69 Thirteen studies28,29,34,38,42-44, 48,53,57,61,69 focused on two or more of these categories (e.g., healthcare use and costs in monetary units), resulting in a total sum greater than 49 studies. In Tables 1-4 the characteristics of the included studies are presented according to healthcare use (Table 1), economic losses by patients and family (Table 2), economic losses in other sectors (Table 3) and costs in monetary units (Table 4).
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Results |
|-----------------------------------|--------|---------------|---------------------------|-------------------------------------|---------------|---------------------------|---------|
| Cagle, 2020, USA                  | Prospective cohort | Mixed cancers (467) | + Died between 2012 and 2014 + Older than 50 years | Depression ssCES-D | Hospice use (yes/no) | Interviews with the person most familiar with the decedent | Not significant Depression and hospice use |
| Champagne, 2018, Canada b         | Longitudinal (follow-up at 0, 2, 10, 14, and 18 months) | Mixed cancers (955) | + Age between 18 and 80 + First cancer diagnosis non-metastatic to be scheduled to receive a surgery + Severe psychiatric disorder + Diagnosed or treated for sleeping disorder | FCR FCR-SF (≥13) | Medical professional: Specialist physician, general practitioner, nurse, pharmacist, homeopath/osteopath, massage therapist Psychosocial professional: social worker psychologist, psychiatrist, physiotherapist Psychotropic medication: Anxiolytics/hypnotics, antidepressants (yes/no) | Study-specific questionnaire | Significant FCR and medical professionals (F = 4.09, p = 0.04) FCR and psychosocial professionals (F = 5.23, p < 0.0001) FCR and anxiolytics/hypnotics (F = 9.88, p = 0.0017) FCR and antidepressants (F = 5.23, p = 0.0499) |
| Compen, 2018, Netherlands b       | Cross-sectional | Mixed cancers (245) | + HADS ≥ 11 + Stable 3 months psychotropic medication + Current active anticancer treatment + Severe psychiatric morbidity + Previous mindfulness intervention | Anxiety, depression and adjustment disorder, psychological distress HADS, SCID-I | Mental healthcare: social workers, psychologists, and psychiatrists Primary healthcare: GP, occupational physicians, and physical and occupational therapists Somatic healthcare: medical outpatient clinics, ED, day health care units, and overnight hospital stays | TIC-P | Significant Depression disorder and mental healthcare (IRR = 1.71 (1.11–2.62)) (p < 0.01) Adjustment disorder and mental healthcare (IRR = 1.77 (1.00–3.10)) (p < 0.05) Distress and mental healthcare (IRR = 1.09 (1.06–1.12)) (p < 0.01) depressive symptoms and mental health (IRR = 1.14 (1.09–1.19)) (p < 0.01) Anxiety symptoms and mental health (IRR = 1.12 (1.07–1.18)) (p < 0.01) Depressive symptoms and primary healthcare use (IRR = 1.04 (1.00–1.08)) (p < 0.05) Not significant Depression, anxiety, adjustment disorder with primary and somatic healthcare use Distress and anxiety with and primary and somatic care Depressive symptoms and somatic healthcare use |
| Faller, 2017, Germany             | Cross-sectional | Mixed cancers (4020) | + Age between 18 and 75 + Evidence of a malignant tumor | Anxiety, depressive symptoms, distress DT (≥5), PHQ (≥9), GAD-7 (≥10) | Utilization of psychological care (yes/no), counseling support (yes/no) | Study-specific questionnaire | Not significant Distress and utilization psychological care (OR = 1.01 (0.95–1.06)) Depression and utilization psychological care (OR = 1.03 (1.00–1.07)) Anxiety and utilization psychological care (OR = 1.06 (1.02–1.10)) |

(Continues)
TABLE 1 (Continued)

| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Results |
|-----------------------------------|--------|---------------|-----------------------------|-------------------------------------|---------------|---------------------------|---------|
| Hamilton, 2019, USA               | Prospective cohort | Mixed cancers (893) | + Having a cancer-related medical appointment + During treatment, standard clinical care | Distress DT (>6) | Service use: social work, psychologist, nutritionist, or chaplain, psychological service use on any inpatient hospitalization | Electronic medical record from the past 12 months (yes/no) (frequency visits) | Significant Distress (continue) and service use (B = 0.03) (p = 0.007) Distress (yes/no) and service use (B = 0.21) (p = 0.004) Distress (>6, continue) and social work (p = 0.001) Distress (>6, continue) and dietetics utilization (p = 0.004) Not significant Distress (>6, continue) and chaplaincy service and psychology service |
| Jacobsen, 2016, USA               | Part of longitudinal (cross-sectional) | Advanced mixed cancer patients (123) | + Older than 20 years + Identified informal care giver + Diagnosis of advanced cancer (presence of distant metastases and failure of first-line chemotherapy | Major depressive disorder SCID | Mental health service use | Study-specific questionnaire | Significant Depression and mental health service use (OR = 16.07 (1.68–153.77)) |
| Jeffery, 2012, USA               | Cross-sectional | Mixed cancers (11,014) | + At least one healthcare service record in fiscal year 2006 + 18 years or older + Survived at least 2 years after their initial cancer treatment – Nonmelanoma skin cancer | Depression Medical record (ICD-9) | Service use: inpatient stays, lengths of inpatient stays, number of outpatient visits (number) Medication: prescriptions (number) | Medical record | Significant Depression (yes/no) mean number of stays (0.41 (0.9) vs. 0.12 (0.4)) Depression (yes/no) mean number of bed days (3.15 (14.39) vs. 0.64 (4.3)) Depression (yes/no) mean number outpatient visits (33.66 (28.84) vs. 18.69 (18.29)) Depression and number of prescriptions (45.28 (33.73) vs. 24.46 (23.51)) All p-values < 0.05 |
| Lo, 2013, Canada                | Retrospective, observational (1 year before measurement of depression, 1 year after depression diagnosis) | Mixed cancer patients (680) | + 18 years or older + Confirmed diagnosis of stage 4 gastrointestinal, breast, gynecologic, or genitourinary cancer, or stage II, III, or IV lung cancer + 451 (173–1036) (median) days since diagnosis + Cognitive impairment documented + Carcinoid or neuroendocrine tumors | Depression Back Depression Inventory II (>20) | Physician visits: primary care mental health, primary care nonmental health and oncology | Administrative databases | Significant Look-back period (1 year before measurement of depression) Depression and primary nonmental healthcare (RR = 1.21 (1.00–1.50)) (p = 0.005) Look-forward (1 year after measurement of depression) Depression and primary care mental health visits (RR = 2.35 (1.18–4.64)) (p = 0.015) Depression and oncology visits (RR = 0.78 (0.65–0.94) (p = 0.008)) (negative association) Not significant Look-back period (1 year before measurement of depression) Depression and primary care mental health visits, oncology visits Look forward period (1 year after measurement of depression) Depression and primary nonmental health visits |
| Mausbach, 2017, USA              | Retrospective cross-sectional | Mixed cancer (5055) | None | Depression Medical record (ICD-9) | Nonmental healthcare visits (number), ED visits, inpatients healthcare use | Medical record (the total number of contacts was calculated as the sum of use categories) | Significant Depression and healthcare visits (RR = 1.76 (1.61–1.93)) (p = 0.001) Depression and ED visits (OR = 2.45 (1.97–3.04)) (p = 0.001) |
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Results |
|-----------------------------------|--------|----------------|----------------------------|---------------------------------------|----------------|---------------------------|---------|
| Mausbach, 2020, California<sup>a</sup> | Retrospective cohort | Mixed cancers (13,426) | + Diagnosis of cancer in 2014 + 18 years or older + At least one healthcare claim within 1 year of cancer diagnosis | Anxiety, depression (electronic medical record) | Electronic medical record | Depression and hospitalization (OR = 1.81 (1.49–2.20) p < 0.001) Depression and 30-days rehospitalization (OR = 2.03 (1.48–2.79) p < 0.001) |
| Pan, 2015, USA<sup>b</sup> | Cross-sectional | Mixed cancer patients (4766) | + Older than 21 years + Reported with cancer in 2006–2009 | Depression (Medical record (ICD-9)) | Inpatient (yes/no), outpatient (yes/no), ED (yes/no), prescription drug (yes/no), and other healthcare services (yes/no) | Study-specific questionnaire | Depression and ED visits (B(SE) = 0.817 (0.074)) (p < 0.001) Depression and hospitalization (B(SE) = 0.584)) (0.076 p < 0.001) Anxiety and ED visits (B(SE) = 0.851 (0.073)) (p < 0.001) Anxiety and hospitalization (B(SE) = 0.704 (0.074)) (p < 0.001) |
| Rana, 2019, Australia | Cross-sectional | Mixed cancers (517) | + Older than 15 years + Diagnosed with any type of cancer | Distress K-10 (four categories: 1 = no, 2 = mild, 3 = moderate, 4 = severe distress) | Doctor visits (yes/no), hospital admissions (>1) | Study-specific questionnaire | Significant Distress a little (compared to never distress) and doctor visits (OR = 1.88 (1.02–3.47)) (p = 0.04) Distress and doctor visits (B = 0.144 (0.110–0.178)) (p = 0.00) Not significant Distress sometimes and most times compared to never and doctor visits Distress most times, sometimes, a little compared to never and hospital admissions Distress and hospital admissions |
| Sarker, 2015, Germany | Cross-sectional | Mixed cancers (335) | + 18 years or older + A malignant tumor (all tumor entities and disease stages) + 12 (21.3–32.9) (mean, SD range) months after cancer diagnosis, – Presence of psychical, psychological and/or cognitive impairments | FCR and anxiety FoP-Q-SF (high FCR > 34), GAD-7 (categorical) | Psychological support services, medical support services, complementary support services, spiritual and religious support services, and other support services (yes/no) | Self-report over 1 year | Not significant FCR and anxiety with psychological support services, medical support services, spiritual and religious support services, and other support services |
| Trevino, 2019, USA | Cross-sectional | Mixed cancer (1211) | + 75 years or older with cancer undergoing surgery + Who were referred to the geriatric services for preoperative evaluation + Underwent elective surgery with a | Distress, depression DT (5–4), GDS (≥1) | Mental healthcare use (social work, psychology, and/or psychiatry clinicians and the patient and/or family) | Electronic medical record | Significant Distress and mental healthcare use (OR = 1.72 (1.16–2.56)) (p = 0.007) Not significant Depression and mental healthcare use (OR = 1.10 (0.73–1.64)) (p = 0.65) |
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Results |
|-----------------------------------|--------|---------------|----------------------------|--------------------------------------|---------------|---------------------------|---------|
| Lebel, 2013, Canada              | Cross-sectional | Breast, prostate, colon, or lung cancer (231) | + 18 years or older + Diagnosed in the past 10 years + 7.2 (SD 2.6) years since diagnosis | FCR FCRI (severity subscale >13) | Outpatient clinic, medical specialist, another healthcare provider, ER, admitted to hospital over the past 6 months (visits) and medication taken in the past week | CBMTG healthcare utilization questionnaire | Significant FCR and outpatient visits (β = 0.16) (p = 0.025)
FCR and ER visits (β = 0.14) (p = 0.047) Not significant FCR and MS visits, medication use, mental healthcare visits and number of overnight visits |
| Fox, 2013, USA                | Retrospective | Breast cancer (40,202) | + 18 years or older + Diagnosis of invasive breast cancer + Procedure for mastectomy – Breast conserving surgery | Psychiatric disorder depression, GAD, adjustment disorder, panic disorder Medical record (ICD-9) | Prolonged hospitalization (>3 days) | NIS reports (electronic medical record) | Significant Psychiatric disorder and prolonged hospitalization (OR = 1.40 (1.32–1.49)) |
| Keyzer-Dekker, 2012, Netherlands | Cross-sectional | Benign or malignant breast disease (151) | + Referral after mammogram + Palpable lump abnormality on a screening mammogram – Medical history with breast cancer or psychiatric disease – Advanced breast cancer | Anxiety and depression STAI, CES-D (cut-off not mentioned) | Medical specialist and GP visits, and use of psychosocial healthcare, that is, psychologist, welfare worker, self-help groups (yes/no) (number visits) | Self-report questions concerning use during first year after diagnosis | Significant Anxiety (low/high level) and psychosocial healthcare use (p = 0.004) Not significant Anxiety and medical specialist and GP visits Depression and psychosocial healthcare use and MS and GP visits |
| Oleske, 2004, USA              | Cross-sectional (retrospective) | Breast cancer (123) | + Women between 21 and 65 and who were expected to survive at least 3 years + At least 1 year after treatment + Mean time since diagnosis, 3.6 years | Symptoms of depression CES-D (≥16) | Any type of hospitalization overnight for any reason | Survey of 27 items about the frequency of visits in the past year | Significant Depressive symptoms and hospitalization (OR = 1.09 (1.03–1.16) (p = 0.041) |
| Otto, 2018, USA                | Cross-sectional | Early breast cancer survivors (303) | + 18 years or older + Diagnosed within the past 7 years + Completed any planned surgeries, chemotherapy, or radiation therapy – Recurrence of breast cancer | FCR FCRI | Frequency of office visits, phone calls oncology medical providers and primary care, sought out mental health (yes/no), psychotropic medication (yes/no) | Self-report over the past 3 months | Significant FCR and oncology visits (RR = 1.53 (1.16–2.01)) (p = 0.002) FCR and phone calls (RR = 2.08 (1.22–3.54)) (p = 0.007) FCR and primary care provider visits (RR = 1.31 (1.06–1.61)) (p = 0.013) Not significant FCR and primary care phone calls, mental health treatment and psychotropic |

**TABLE 1 (Continued)**
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Results |
|-----------------------------------|--------|----------------|-----------------------------|-------------------------------------|---------------|-----------------------------|---------|
| Thewes, 2012, Australia           | Cross-sectional | Early breast cancer (218) | + Age between 18 and 45 + Early breast cancer (stage 0–2) + Diagnosed at least 1 year ago + Completed hospital-based treatment, no history of recurrent disease or new primary cancer + 50 months (mean) after diagnosis | FCR (severity subscale >13) (subscale 0–36) | GP and oncologist visits, other healthcare usage (professional counselling, participation in support groups and membership of consumer advocacy groups (yes/no)) | Self-report over the past 12 months | Significant FCR and GP visits (yes/no) (9.9 (2.3 to 17.4)) (p = 0.01) FRC and mammograms (once or more per year/no) (~18.2 ~29.1 to ~7.3) (p = 0.001) (negative association) FCR and other screening practices (yes/no) (~10.9 ~20.7 to ~1.2) (0.003) (negative association) FCR and current counselling (19.4 (48 to 33.9)) (p = 0.009) FCR and support group (10.9 (0.2 to 21.6)) (p = 0.05) |
| Vachon, 2020, USA                 | Cross-sectional | Breast cancer (1127) | + 45 years or younger or age between 55 and 70 years + Initial cancer diagnosis at stages I-IIa + 3 till 8 years post initial treatment at time enrollment study + Been treated with an adjuvant chemotherapy regimen – No cancer recurrence | FCR Concerns About Recurrence Scale Total Worries Index | Cancer-related healthcare use (routine follow-up, visiting healthcare provider, ER), no cancer-related healthcare use (visiting healthcare provider, ER) | Study-specific questionnaire about healthcare use past 12 months | Significant FCR and routine follow-up care cancer (IRR = 1.003, SE = 0.01, p = 0.02) Not significant FCR and ER (related to cancer, ER (not related to cancer), healthcare provider visits (related to cancer), annual healthcare provider visits (not related to cancer) |
| Other single tumor types          |         |                |                             | Psychological distress HADS (≥ 13) | Receiving psychological care (yes/no), ≥ 3 GP contact (yes/no), ≥4 medical specialist visit (yes/no) | Study-specific questionnaire (recall period of 12 months) | Significant Distress and receiving psychological care (OR = 2.19 (1.62–2.98)) (p < 0.05) Distress and contacting GP (OR = 2.06 (1.57–2.69)) (p < 0.05) Distress and medical specialist visit (OR = 1.80 (1.36–2.38)) (p < 0.05) |
| Arts, 2018, Netherlands           | Cross-sectional | Lymphoma and chronic lymphocytic leukemia (1444) | + 18 years or older + Cancer survivors – No terminal care | Depression Medical records | GP consults, prescriptions, outpatient and inpatient | Medical records (1 year) | Significant Depression and prescription, inpatient and outpatient (women) Depression and prescription, inpatient and outpatient (men) Not significant Depression and GP consultations (women) |
| Bhattarai, 2013, UK               | Retrospective cohort | Colorectal cancer | + Age between 30 and 100 + Registered at a contributing practice | Anxiety PROMIS anxiety | Unplanned clinic or ER encounter within 30 days after surgery (yes/no) | Hospital electronic medical record (30 days) | Not significant Healthcare use (yes/no) group had higher anxiety scores than healthcare use (no) group (58.3 vs. 53.8) (p = 0.06) |
| Doll, 2016, USA                   | Longitudinal (follow-up at 1, 3, 6 months) | Gynecologic cancer (185) | + Age older than 18 + Newly diagnosed gynecologic cancer and planned surgical management. – Active chemo or radiotherapy treatment | Anxiety PROMIS anxiety | Unplanned clinic or ER encounter within 30 days after surgery (yes/no) | Hospital electronic medical record (30 days) | (Continues) |
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Results |
|-----------------------------------|--------|---------------|---------------------------|-------------------------------------|---------------|---------------------------|---------|
| Godby, 2020, USA                  | Cross-sectional | Gastrointestinal cancer (355) | + 18 years or older + Patients who were chemotherapy naïve | Depressive symptoms PROMIS (≥60) | ER visits and hospitalization prior year (yes/no), daily medication use past 7 days (yes/no) | Cancer & Aging Resilience Evaluation survey | Significant Depression symptoms and daily medication use (OR = 2.51 (1.21–5.20)) Not significant Depressive symptoms and ER visits and hospitalization |
| Holla, 2016, Netherlands          | Cross-sectional | Colorectal cancer (3957) | + Older than 18 years + Undergone surgery with or without radiotherapy or chemotherapy − Cognitive impairments | Anxious and depressive mood HADS | Supportive care (dietician, oncolgical nurse, physical therapist, psychologist, completion rehabilitation program) (yes/no), number of visits from GP and medical doctor (number of visits) | Study-specific questionnaire | Significant Anxiety and dietary care (OR = 1.09 (1.06–1.12)) (p < 0.01) Anxiety and oncological nursing care (OR = 1.07 (1.04–1.11)) (p < 0.01) Anxiety and physical therapy (OR = 1.06 (1.03–1.09)) (p < 0.01) Anxiety and psychological care (OR = 1.18 (1.13–1.22)) (p < 0.01) Anxiety and rehabilitation program (OR = 1.08 (1.05–1.12)) (p < 0.01) Depression and dietary care (OR = 1.10 (1.07–1.13)) (p < 0.01) Depression and oncological nursing care (OR = 1.06 (1.03–1.10)) (p < 0.01) Depression and physical therapy (OR = 1.06 (1.03–1.09)) (p < 0.01) Depression and psychological care (OR = 1.15 (1.11–1.20)) (p < 0.01) Depression and rehabilitation program (OR = 1.06 (1.02–1.10)) (p < 0.01) |
| Jayadevappa, 2012, USA           | Longitudinal 1 year prior to diagnosis, and 5 years post-diagnosis | Prostate cancer (50,147) | + Older than 66 years + 1 year prior to diagnosis, and 5 years post-diagnosis, in case the patient died, 1 year prior to death was called terminal phase | Depression Medical record (ICD-9) | Inpatient (length of stay, number of admissions, surgical and diagnostic procedures), outpatient (laboratory testing and ER visits), durable medical equipment, home health services, skilled nursing facility use and hospice care) | SEER-Medicare linked data (1 year prior to diagnosis, and 5 years post-diagnosis) | Significant Depression in treatment phase and ER visits (OR = 3.46 (3.21–3.74)) Depression in post-treatment phase and ER visits (OR = 1.64 (1.54–1.74)) Depression in treatment phase and hospitalization (OR = 2.76 (2.63–2.88)) Depression in post-treatment phase and hospitalization (OR = 1.34 (1.29–1.39)) Depression in treatment phase and outpatient visits (OR = 1.80 (1.76–1.85)) Depression in post-treatment phase and outpatient visits (OR = 1.52 (1.50–1.80)) |
| Jeffery, 2019, USA               | Retrospective cross-sectional | Head and neck cancer (2944) | + Age between 18 and 64 + Had a primary diagnosis of head | Anxiety, depression and adjustment | Annual number of ambulatory visits, hospital admission | ICD-9 codes | Significant Depression and ambulatory visits (WX2 = 2765.48) (p < 0.0001) |
| First author, year, study location | Design    | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Results* |
|-----------------------------------|-----------|----------------|-----------------------------|-------------------------------------|----------------|-----------------------------|----------|
| Laurence, 2017, USA              | Retrospective | Head and neck cancer (36,420) | + 50 years and older – Cancers of the lip, salivary glands, nasopharynx, and thyroid | Depression Medical record (ICD-9-M) | ED visit (ended in admission vs. discharge) | Data from Nationwide Emergency Department sample (2008) (ICD-codes) | Significant |
|                                   |           |                |                             |                                     |                |                             | Head and neck cancer |
|                                   |           |                |                             | Depression and hospital admission men (PR = 1.28) (1.21–1.36) (p < 0.001) | Depression and hospital admission women (PR = 1.31) (1.20–1.42) (p < 0.001) | | |
|                                   |           |                |                             | Larynx/Hypopharynx Depression and hospital admission men (PR = 1.21) (1.21–1.30) (p < 0.001) | Depression and hospital admission women (PR = 1.27) (1.16–1.40) (p < 0.001) | | |
|                                   |           |                |                             | Oral cavity Depression and hospital admission men (PR = 1.14) (1.06–1.24) (p < 0.001) | Depression and hospital admission women (PR = 1.56) (1.25–1.94) (p < 0.001) | | |
|                                   |           |                |                             | Not significant | Oral cavity | Depression and hospital admission women (PR = 1.29) (0.98–1.70) (p = 0.330) | | |
| Lee, 2018, Taiwanβ               | Population-based cohort study retrospectively | Hepatocellular carcinoma (223 matched with non-disorder (anxiety and depression) group) | + Treated between 1996 and 2010 + 18 years or older + History of HHC enrolment in registry for catastrophic illness patient database | Anxiety/depression Medical record (ICD-9) | Physician visits and lengths of stay hospital | Administrative claims for reimbursement from the Taiwan Bureau of National Health insurance | Significant |
|                                   |           |                |                             |                                     |                |                             | Usage 1 year after diagnosis |
|                                   |           |                |                             | Anxiety/depression and physician visits (diff. = 48.2 (0.3)) (p < 0.001) | Anxiety/depression and length of stay (diff. = 9.0 (0.4)) (p < 0.001) | | |
|                                   |           |                |                             | Usage 5 years after diagnosis | | | |
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Resultsa |
|-----------------------------------|--------|----------------|----------------------------|-------------------------------------|---------------|---------------------------|----------|
| McDermott, 2018, USA              | Cross-sectional | Advanced non-small-cell lung cancer (13,827) | + Older than 67 years + Diagnosed with stage III B or IV in 2007-2011 and claims spanning 2007-2013 | Depression ICD-9 (diagnosis-time depression/post-diagnosis depression) | Hospice use > 3 days and > 90 days, > 1 inpatient, in-hospital death, > 1 ED visits, > 1 hospitalizations, or ICU admission in the last 30 days of life, or chemotherapy receipt in the last 14 days | Electronic medical record | Significant Post-diagnosis depression and ICU admission (OR = 1.18 (1.01–1.37)) Not significant Diagnosis-time depression and inpatient admission, ICU admission, in-hospital death, ED visits and chemotherapy in last 14 days Post-diagnosis depression and inpatient admission, in-hospital death, ED visits and chemotherapy in last 14 days |
| Mosher, 2013, USA                 | Cross-sectional | Lung cancer (165) | + 18 years or older have/had cancer treatment + 18 (22) months (mean, SD) after cancer diagnosis + Not too ill to participate in the study | Anxiety and depressive symptoms HADS (>9, >8) | Mental health services, including psychotherapy/ counselling/ psychotropic medication and support groups, spiritual leader | Patient-reported questionnaire | Not significant Depression and anxiety and mental health use and help of spiritual leader |
| Niazi, 2018, USA                  | Cross-sectional | Multiple myeloma (36,007) | + Diagnosed between 1991 and 2010 with multiple myeloma + Full medical coverage | Depression ICD-9 (yes/no) | Inpatient, outpatient, ambulatory claims | SEER-Medicare (use and costs within the first 6 months after the diagnosis) | Significant Depression and undergoing inpatient (OR = 1.41, (1.31–1.53)) Depression and ED (OR = 1.37 (1.28–1.47)) Depression and ambulatory care. (OR = 1.22 (1.14–1.30)) all p < 0.001 |
| Nipp, 2017, USA                   | Unclear        | Mixed cancer (1036) | + Older than 18 years and palliative + Advanced cancer + Not treated with curative intent − Excluded patients with leukemia and those who were admitted for stem cell transplantation − Patients with elective or planned hospital admissions | Depression, anxiety and distress PHQ-4 (>3 per subscale) (continues for distress) | Hospital length of stay, unplanned hospital admissions | Medical record | Significant Anxiety and time readmission within 90 days (HR = 1.059 (1.001–1.119)) (p = 0.045). Not significant Depression and anxiety and hospital length of stay. Depression and time to readmission within 90 days |
| Schuurhuize, 2019, Netherlands     | Longitudinal, after 10, 24, and 48 weeks of treatments | Metastatic colorectal cancer (349) | + Diagnosis of metastatic colorectal cancer and started first line systemic treatment | Distress HADS (≥13), DT (≥5) | Psychosocial service utilization (yes/no) | Tic-P | Not significant Depression and psychosocial service utilization Distress and psychosocial service utilization |
| X. Han, 2015, USA                 | Cross-sectional | Mixed cancers (3309) | + History with cancer + Older than 18 years − Nonmelanoma skin cancer | Psychological distress K6 (≥11) | Medical provider visits, number of hospital outpatient visits, number of inpatient discharges, number of emergency department visits, Survey and contacting medical providers | | Significant among mixed cancer Distress (no/yes), hospital outpatient visits 35.3% versus 43.3% (p = 0.0153) Distress (no/yes), hospital inpatient discharge 16.0% versus 43.3% (p = 0.0003) Distress (no/yes), emergency visits 17.5% versus 35.3% (p < 0.0001) Distress (no/yes), dental visits 53.1% versus 27.1% |
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare use | Measurement healthcare use | Results* |
|-----------------------------------|--------|---------------|----------------------------|-----------------------------------|----------------|---------------------------|----------|
|                                   |        |               |                            | dental visits, number of prescribed medicines |                |                           |          |
|                                   |        |               |                            |                                   |                |                           |          |
| *Significant results in this column indicate a positive association between psychological problems and healthcare use, unless otherwise specified. |
| Article is also presented in Tables 2, 3 or 4. |

Abbreviations: CBMTG, Canadian Blood and Marrow Transplant group; CES-D, Center for Epidemiologic Studies Depression Scale; Diff, difference; DT, distress thermometer; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; ED, emergency department; ER, emergency room; FCR, fear of cancer recurrence; FCR-7, Fear of Cancer Recurrence Inventory-short form; FOP-Q-SF, Fear of Progression Questionnaire – Short Form; GAD, generalized anxiety disorder; GAD-7, generalized anxiety disorder-7; GDS, Geriatric Depression Scale; GP, General practitioner; HADS, Hospital Anxiety and Depression Scale; HHC, hepatocellular carcinoma; ICD-9-CM, International Classification of Diseases; ICU, intensive care; IRR, incidence rate ratios; K6, Kessler-6; MS, Medical specialist; NIS, Nationwide Inpatient Sample; OR, odds ratio, PHQ, Patient Health Questionnaire; PR, prevalence ratio; PROMIS, Patient-Reported Outcomes Measurement Information System; SCID, Structured Clinical Interview for DSM-IV; SF, short form; STAI, State-Trait Anxiety Inventory; TIC-P, The Trimbos/IMTA questionnaire for costs associated with psychiatric illnesses.
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Losses of patients and family | Measurement healthcare use | Results* |
|-----------------------------------|--------|---------------|---------------------------|-------------------------------------|-------------------------------|---------------------------|----------|
| Champagne, 2018, Canadab | Longitudinal (follow-up at 0, 2, 10, 14 and 18 months) | Mixed cancers (955) | + Age between 18 and 80 + First cancer diagnosis nonmetastatic to be scheduled to receive a surgery ≈ Severe psychiatric disorder ≈ Diagnosed or treated for sleeping disorder | FCR FCRI-SF (≥13) | CAM: homeopath/osteopath, massage therapist, chiropractor, acupuncturist, and other | Study-specific questionnaire | Not significant FCR and CAM (F = 1.25, p = 0.264) |
| Thewes, 2012, Australiab | Cross-sectional Early breast cancer (218) | + Age between 18 and 45 + Early breast cancer (stage 0–2) + Diagnosed at least 1 year ago + Completed hospital-based treatment, no history of recurrent disease or new primary cancer + 50 months (mean) after diagnosis | FCR FCRI (severity subscale >13) (subscale 0–36) | CAM: professional counselling, massage, physiotherapy, lymphedema therapy, chiropractics, medications for anxiety, or depression, medication for sexual dysfunction, naturopathy, herbs, homeopathy, Reiki, acupuncture, meditation, yoga, hydrotherapy, hypnosis, Chinese medicine, reflexology, prayer or spiritual healing | Self-report over the past 12 months | Significant FCR and number of CAM used (1.8 (0.2–3.5)) (p = 0.03) Not significant FCR and CAM use (yes/no) |
| Manne, 2015, USA | Cross-sectional Early-stage breast cancer (143 patients and spouses) | + Patients had breast cancer surgery + 18 years or older + Spouses worked for the past month | Cancer-specific distress (Impact of Event Scale) | Healthcare use by spouses: Visits of different types of physicians in the past year (e.g., internist, cardiollogist, urologist, radiologist, surgeon, oncologist, and neurologist) Losses of work productivity and absenteeism of the spouses | HPQ, questionnaire | Significant Patient cancer distress and healthcare use spouses (correlation = −0.23) (<0.05) (negative) Patient cancer distress and losses of work productivity of spouses (correlation = 0.18) (p < 0.05) Patient cancer distress and spouses absenteeism (correlation = 0.18) (p < 0.05) |
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Losses of patients and family | Measurement healthcare use | Results* |
|-----------------------------------|--------|---------------|-----------------------------|--------------------------------------|-------------------------------|-----------------------------|----------|
| Compen, 2018, Netherlands*         | Cross-sectional | Mixed cancers (245) | + HADS ≥ 11  
+ Stable 3 months psychotropic medication  
+ Current active anti-cancer treatment  
+ Severe psychiatric morbidity  
+ Previous mindfulness intervention | Anxiety, depression and adjustment disorder psychological distress HADS, SCID-I | CAM: homeopaths, acupuncturists, traditional Chinese medicine, and massage therapists | Tic-P | Significant  
Distress and complementary healthcare (IRR = 1.03 (1.00–1.06)) (p < 0.05)  
Anxiety symptoms and complementary healthcare (IRR = 1.06 (1.01–1.11)) (p < 0.05)  
Not significant  
Depression, anxiety and adjustment disorder and depressive symptoms with complementary healthcare use |
| Litzelman, 2020, USA              | Cross-sectional | Spouses of mixed cancer patients (1882) and mixed cancer patients (1882) | − Nonmelanoma skin cancer  
− Patients with missing data  
− If spousal reported cancer diagnosis | Distress, depressive mood K6 (≥ 3.5), PHQ-2 (≥ 3) >5 | Mental healthcare use of spouses (antidepressant, antianxiety medication, psychotherapy visit) (any/none) | Medical Expenditure Panel Survey | Significant  
Elevated depressed mood and mental healthcare use spouses (OR = 0.59 (0.36–0.96)) (negative)  
Not significant  
Elevated distress and mental healthcare use spouses |
| Sarker, 2015, Germany             | Cross-sectional | Mixed cancers (335) | + 18 years or older  
+ A malignant tumor (all tumor entities and disease stages)  
+ 12 (21.3–22.8) (mean, SD range) months after cancer diagnosis,  
− Presence of psychological, psychological and/or cognitive impairments | FCR and anxiety FoP-Q-SF (high FCR >34), GAD-7 (categorical) | CAM (yes/no) | Self-report over 1 year | Not significant  
FCR and CAM use |

Abbreviations: CAM, complementary and alternatively medicine; FCR, fear of cancer recurrence; FCRI-SF, Fear of Cancer Recurrence Inventory-short form; FOP-Q-SF, Fear of Progression Questionnaire – Short Form; HPQ, World Health Organization Health and Work Performance Questionnaire; IRR, incidence rate ratios; PHQ, Patient Health Questionnaire; SCID, Structured Clinical Interview for DSM-IV; SF, short form; Tic-P, The Trimbos/IMTA questionnaire for costs associated with psychiatric illnesses.

*Significant results in this column indicate a positive association between psychological problems and losses of patients and family, unless otherwise specified.

*Article is also presented in Tables 1, 3 or 4.
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome | Work productivity | Measurement instrument work productivity | Results* |
|-----------------------------------|--------|----------------|----------------------------|-----------------------|------------------|----------------------------------------|----------|
| Den Bakker, 2019, Netherlands      | Cross-sectional (retrospective registry based cohort) | Colorectal cancer (317) | + 18 years or older  
+ Treated with curative intent  
− Diagnosis of recurrent colorectal cancer  
− Another cancer diagnosis during sick leave | Emotional distress | RTW (1 and 2 years after diagnosis) | Study-specific questionnaire | Significant  
Distress and RTW after 1 year (OR = 0.47 (0.25-0.89)) (p = 0.020)  
Distress and RTW after 2 years (OR = 0.39 (0.22–0.67)) (p = 0.001) |
| Dumas, 2020, France               | Prospective cohort (baseline at diagnosis, 3–6 months after treatment and 2 years after diagnosis) | Breast cancer (1874) | + Diagnosed stages I–III  
+ Younger than 57 years  
− History of cancer within the past 5 years  
− Women without information about work situation  
− Not employed at diagnosis  
− Not treated with curative intent | Anxiety and depression  
HADS (non-case: 0–7, doubtful case: 8–10, case: 11–21) | RTW (2 years after diagnosis) | Study-specific question | Significant/not significant  
Depression (case/non-case) and RTW (OR = 2.29 (1.34–3.91))  
Anxiety (case/non-case) and RTW (OR = 1.47 (1.02–2.11))  
Anxiety (doubtful case/non-case) and RTW (OR = 1.71 (1.26–2.32)) |
| Horsboel, 2015, Denmark           | Longitudinal (1 year follow-up) | Hematological malignancy (105) | + Age between 19 and 59  
+ 6–9 months diagnosed prior to inclusion  
+ Employed at inclusion | Anxiety and depressive symptoms  
HADS (>8 and > 11) | RTW (1 year after diagnosis and long sickness absence) | Register for evaluation of marginalization (DREAM). | Not significant  
Depression (doubtful case/non-case) and RTW |
| Landeiro, 2018, Brazil            | Longitudinal (6, 12, 24 months after diagnosis) | Breast cancer (121) | + Age between 18 and 57  
+ <5 months post-diagnosis  
+ Employed at diagnosis  
− Pregnancy  
− A Previous cancer diagnosis  
− Not insured | Depression | RTW (2 years after diagnosis) | Study-specific questionnaire | Significant  
Depression and reduced RTW (OR = 0.07 (0.01–0.63)) (p = 0.017) |
| Rosbjerg, 2020, Denmark           | Longitudinal (followed \15 months after baseline) | Mixed cancer (114) | + Age between 18 and 62  
+ All treatment intentions  
+ Initiating chemotherapy last 24 months  
+ Employed at time of diagnosis  
+ Time since diagnosis (69,5 days (mean)) | Depression | RTW (follow-up till 15 months after baseline) | DREAM database | Significant  
Symptoms of depression and RTW (HR = 0.58 (0.32–1.07)) (p = 0.082) |
TABLE 3  (Continued)

| First author, year, study location | Design       | Tumor type (N) | In- and exclusion criteria                                                                 | Psychological outcome | Work productivity | Measurement instrument   | Work productivity | Resultsa |
|-----------------------------------|--------------|----------------|-------------------------------------------------------------------------------------------|-----------------------|-------------------|--------------------------|-------------------|----------|
| Schmidt, 2019, Germany            | Retrospective study | Breast cancer (135) | + Completed the 5 years follow-up after surgery  
+ Been employed at time of diagnosis  
− Patients who were during follow-up no longer disease free or not at working age (≥65) | Depressive symptoms CES-D | Impaired RTW (1 and 5 years after breast surgery) | Study-specific questionnaire | Impaired RTW | Significant  
Depressive symptoms at end of surgery and RTW 1 year after surgery (OR = 2.9 (1.1–8.0))  
Not significant  
Depressive symptoms 1.5 years after surgery and RTW 5 years after surgery |
| Schonfeld, 1972, USA              | Longitudinal  | Mixed cancer (42) | + Good or excellent prognosis for 5 years survival  
+ Fulltime working before diagnosis  
− No malignancies | Anxiety levels IPAT anxiety scale questionnaire | RTW (9 months after first interview) | Interview | Significant  
Anxiety (higher) and RTW (p = 0.02), anxiety score: Working 20.2 versus not working 28.8 |
| Spelten, 2003, Netherlands        | Longitudinal  | Mixed cancers (214) | + Age between 18 and 60  
+ Treatment with curative intent  
+ Paid employment at time of diagnosis  
+ Within 4–6 months following their first day of sick leave | Depression CES-D | RTW (6, 12 and 18 months after first sick leave) | Self-report | Significant  
Depression quartiles and RTW (HR = 0.81 (0.66–0.99)) |

Abbreviations: CES-D, Center for Epidemiologic Studies Depression Scale; HADS, Hospital Anxiety and Depression Scale; ICD-9-CM, International Classification of Diseases; IPAT, Intensive Care Psychological Assessment Tool; K6, Kessler-6; RTW, return to work; SCID, Structured Clinical Interview for DSM-IV.

aSignificant results in this column indicate a negative association between psychological problems and return-to-work, unless otherwise specified.
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare costs categories | Measurement healthcare use and cost valuation | Results |
|-----------------------------------|--------|----------------|---------------------------|--------------------------------------|----------------------------|-----------------------------------------------|----------|
| Compen, 2018, Netherlands<sup>a</sup> | Cross-sectional | Mixed cancers (245) | + HADS ≥ 11  
+ Stable 3 months psychotropic medication  
− Severe psychiatric morbidity  
− Previous mindfulness intervention | Anxiety, depression and adjustment disorder psychological distress SCID-I, HADS | Mental healthcare including visits to social workers, psychologists, and psychiatrists. Primary healthcare including visits to GP, occupational physicians, and physical and occupational therapists. Somatic healthcare including visits to medical outpatient clinics, ED, day healthcare units, and overnight hospital stays, prescription medication costs. Complementary healthcare utilization including visits to homeopaths, acupuncturists, traditional Chinese medicine, and massage therapists | Trimbos/IMTA questionnaire for costs associated with psychiatric illnesses (TiC-P), calculated into costs using Dutch reference prices | Significant Depression disorder and mental healthcare (OR = 3.44 (1.56–7.12))  
Anxiety disorder and mental healthcare (OR = 3.92 (1.58–9.73))  
Distress and mental healthcare (OR = 1.09 (1.04–1.14)) (B = 1.04 (1.01–1.07))  
Depressive symptoms and mental healthcare (OR = 1.16 (1.07–1.25))  
Anxiety symptoms and mental healthcare (OR = 1.11 (1.03–1.20)) (B = 1.11 (1.05–1.16)) | |
| Gu, 2020, USA | Retrospective cohort study | Mixed cancer (breast, lung, prostate) (710) | + At least one inpatient and two outpatient claims or medical provider claim  
− Patients lost with follow-up | Depression study-specific questionnaire (yes/no) | Healthcare expenditures (medicine, dental, home health, hospice inpatient, nursing facilities, outpatient) | Over 24 months since year of diagnosis. Medicare Current Beneficiary Survey (MCBS)-Medicare sponsored by the Centers for Medicare & Medicaid services (index year 2017) | Significant Depression (yes/no) and medical provider (B = 0.36 (0.1))  
(Change $ = 11,454 (4472–19,729) (p < 0.001)  
Depression (yes/no) and inpatient  
(AOR = 2.94 (1.82–4.74))  
(Change $ = 8213 (3477–13,998) (p < 0.001)  
Depression (yes/no) and other  
(B = 0.41 (0.16)  
(Change $ = 405 (69–870) (p < 0.05)  
Depression (yes/no) and Medicare  
(B = 0.37 (0.01)  
(Change $ = 8280 (3570–13,977) (p < 0.001)  
Depression (yes/no) and out of pocket  
(B = 0.28 (0.13) | Not significant Depression disorder, anxiety disorder, adjustment disorder, distress, anxiety symptoms and depressive symptoms with primary, somatic and complementary healthcare  
Depressive disorder, anxiety disorder, adjustment disorder and depressive symptoms with mental healthcare |
| First author, year, study location | Design          | Tumor type (N)                  | In- and exclusion criteria                                                                 | Psychological outcome (measurement)           | Healthcare costs categories                                                                 | Measurement healthcare use and cost valuation                                                                 | Results                                                                                               |
|-----------------------------------|-----------------|---------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| Pan, 2015, USA<sup>a</sup>        | Cross-sectional | Mixed cancer patients (4766)    | + Older than 21 years <br>+ Reported with cancer in 2006-2009                             | Depression <br>Medical record (ICD-9-CM)    | Inpatient and outpatient care, emergency department visits, prescriptions, home healthcare, durable medical equipment, dental care, eye care, and others types of healthcare (1 year) | The sum of all direct actual third-party payments made to the providers for services rendered plus the out-of-pocket spending by the individual or family (index year 2009) | (Change $ = 1270 (139–2720) <br>0.01 ≤ p < 0.05) Not significant Depression and hospital outpatient and prescribed medicine |
| Mausbach, 2018, California<sup>b</sup> | Cross-sectional | Mixed cancer patients (13,233)  | + 18 years or older <br>+ At least one healthcare claim within 1 year of the cancer diagnosis | Depression <br>Medical record (ICD-9-CM)    | Annual outpatient (ambulatory) office visits, ED visits, hospital visits, and mental health visits | Provided by the UC San Diego health cost-accounting system (electronic records)                                                                 | Significant Depression and total charges ($B = 9.136) <br>p < 0.001 Depression and outpatient costs ($B = 8.468) <br>p < 0.001 Depression and prescription costs <br>p < 0.001 |
| Mausbach, 2020, California<sup>c</sup> | Retrospective cohort | Mixed cancers (13,426)          | + Diagnosis of cancer in 2014 <br>+ 18 years or older <br>+ At least one healthcare claim within 1 year of cancer diagnosis | Anxiety, depression <br>Medical record (ICD-9-CM) | Healthcare costs (total annual healthcare charges, annual outpatient (ambulatory) office charges, ED charges, and inpatient hospital charges) | Provided by the UC San Diego health cost-accounting system (electronic records)                                                                 | Significant Depression and total charges ($B = 1.38 <br>(1.25–1.52) <br>p < 0.001) Depression and ambulatory charges ($B = 1.44 (1.35–1.52) <br>p = 0.001) Depression and ED charges ($B = 1.26 <br>(1.13–1.40) <br>p < 0.001) Depression and inpatient hospital charges ($B = 1.21 (1.09–1.35) <br>p < 0.001) |

(Continues)
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare costs categories | Measurement healthcare use and cost valuation | Results |
|----------------------------------|--------|----------------|-----------------------------|-------------------------------------|-----------------------------|-----------------------------------------------|---------|
| Boele, 2020, Netherlands          | Longitudinal (6, 12, 18, 24 weeks and 6 and 12 months follow-up) | Glioma patients (90) | + 18 years or older + Glioma patients with I, II, III stage + CES-D score ≥ 12 + 3.4 years (mean) time since diagnosis – Suicidal intent | Depression CES-D | Direct costs of healthcare utilization from appointments and medication (including oral chemotherapy, but excluding procedures such as surgery and/or radiotherapy), and indirect costs due to productivity loss in three modules: absence from paid employment; production loss without absence from paid employment; and impediments to paid or unpaid employment | Trimbos/iMTA questionnaire for costs associated with psychiatric illness (TIC-P) including the Short-Form Health and Labor Questionnaire (SF-HLQ) (index year 2019) | Significant Depression and healthcare utilization costs (+€24,459 [3662–42,250] per 4 weeks with each unit increase in scores) (p = 0.001) Not significant Depression and medication costs, overall costs and productivity loss costs |
| Fox, 2013, USA                   | Retrospective | Breast cancer (40,202) | + 18 years or older + Procedure for mastectomy – Breast conserving surgery | Psychiatric disorder (i.e., major depression, GAD, adjustment disorder, panic disorder) Medical record (ICD-9) | Total healthcare costs | NIS reports (electronic medical record), actual charges (index year 2008) | Significant Psychiatric disorder and costs (p < 0.001) |
| Jayadevappa, 2012, USA          | Longitudinal (1 year prior to diagnosis, and 5 years post-diagnosis) | Prostate cancer (50,147) | + Older than 66 years | Depression Medical record (ICD-9) | Direct medical costs: physicians and other health professionals, care provided in hospitals, outpatient and ER costs, inpatient medications | SEER-Medicare linked data (index year 2009) | Significant Treatment phase depression and costs year of diagnosis (OR = 1.52 [1.39–1.66]) |

Anxiety and total charges (B = 1.77 (1.61–1.94)) (p < 0.001) Anxiety and ambulatory charges (B = 1.54 (1.46–1.64)) (p < 0.001) Anxiety and total charges (B = 1.29 (1.16–1.44)) (p < 0.001) Anxiety and inpatient hospital charges (B = 1.31 (1.18–1.46) (p < 0.001)
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare costs categories | Measurement healthcare use and cost valuation | Resultsa |
|----------------------------------|--------|----------------|-----------------------------|-------------------------------------|-----------------------------|---------------------------------------------|-----------|
| Jeffery, 2019, USAb | Cross-sectional (retrospective) | Head and neck cancer (2944) | + Age between 18 and 64 + The rank of the military sponsor was enlisted or officer + Healthcare was delivered within the United States | Anxiety, depression and adjustment disorder | Total annual reimbursed cost adjusted to 2014 dollars | Military data repository (index year 2014) | Significant Depression and total costs \( (B = 0.30 (0.024–12.53)) \) \( (p < 0.0001) \) Anxiety and total costs \( (B = 0.26 (0.027–9.51)) \) \( (p < 0.0001) \) Adjustment disorder and total costs \( (B = 0.23 (0.036–6.21)) \) \( (p < 0.0001) \) |
| Jeffery, 2012, USAb | Cross-sectional | Mixed cancers (11,014) | + At least one healthcare service record in fiscal year 2006 + 18 years or older + Survived at least 2 years after their initial cancer treatment − Nonmelanoma skin cancer | Depression | Total costs | Total cost that were reimbursed or paid to the provider in fiscal year 2009 Costs incurred by the patient or covered by other health/insurance were not included. | Significant Depression yes/no and mean costs per provider \( (7728 (13,104) versus 16,212 (30,874)) \) \( (p < 0.05) \) |
| Lee, 2018, Taiwanb | Population-based cohort study retrospectively | Hepatocellular carcinoma (223 matched with non-disorder (anxiety and depression) group) | + Treated between 1996 and 2010 + 18 years or older + History of HHC enrolment in registry for catastrophic illness patient database | Anxiety and depression | Outpatient costs, inpatient costs and total treatment costs (1 and 5 years after diagnosis) | Administrative claims for reimbursement from the Taiwan Bureau of National Health insurance | Significant Year 1 after diagnosis costs Anxiety/depression and inpatient cost \( (\text{diff.} = 1251) \) Anxiety/depression and outpatient cost \( (\text{diff.} = 1665) \) Anxiety/depression and treatment cost \( (\text{diff.} = 2969) \) Year 5 after diagnosis costs (Continues) |
| First author, year, study location | Design          | Tumor type (N)         | In- and exclusion criteria                                                                 | Psychological outcome (measurement) | Healthcare costs categories                                                                 | Measurement healthcare use and cost valuation | Resultsa |
|-----------------------------------|-----------------|------------------------|------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------|---------|
| Niazi, 2018, USAb                  | Cross-sectional | Multiple myeloma (36,007) | + Diagnosed between 1991 and 2010 + Full medical coverage                                   | Depression                          | Total healthcare costs (within the first 6 months after the diagnosis)                      | SEER-Medicare (index year 2013)               | Anxiety/depression and inpatient cost (diff. = 2079) Anxiety/depression and outpatient cost (diff. = 3345) Anxiety/depression and treatment cost (diff. = 5303) All p values are <0.001 |
| Han, 2015, USAb                    | Cross-sectional | Mixed cancers (3309)   | + History with cancer + Older than 18 years − Nonmelanoma skin cancer                   | Psychological distress K6 (≥13)     | Medical provider visits, hospital outpatient visits, inpatient discharges, emergency department visits, dental visits, prescribed medicines and total expenditures | Survey and contacting medical providers       | Significant in mixed cancers Distress (no/yes), hospital outpatient costs 35.0% versus 43.3% (p = 0.0013) Distress (no/yes), hospital inpatient costs 15.9% versus 27.2% (p = 0.0006) Distress (no/yes), emergency costs 16.3% versus 33.9% (p < 0.0001) Distress (no/yes), dental visit costs 52.0 versus 26.8 (p < 0.0001) (negative) Distress (no/yes), home healthcare costs 5.5 versus 16.5 (p < 0.0001) Distress (no/yes), medicine prescriptions costs 90.6 versus 95.5 (p = 0.0011) Significant in prostate cancer Distress (no/yes), office-based costs 95.7% versus 99.3% (p = 0.0195) Distress (no/yes), emergency costs 15.9% versus 41.9% (p = 0.0322) Distress (no/yes), medication prescriptions costs 94.3% versus 99.3% (p = 0.0135) |
| First author, year, study location | Design | Tumor type (N) | In- and exclusion criteria | Psychological outcome (measurement) | Healthcare costs categories | Measurement healthcare use and cost valuation | Results<sup>a</sup> |
|----------------------------------|--------|----------------|-----------------------------|-------------------------------------|-----------------------------|---------------------------------------------|-------------------|
|                                  |        |                |                             |                                     |                             |                                             | Significant in colorectal cancer Distress (no/yes), dental visits costs 46.5% versus 12.2% ($p = 0.0032$) |
|                                  |        |                |                             |                                     |                             |                                             | Significant in breast cancer Distress (no/yes), hospital inpatient costs 11.7% versus 27.0% ($p = 0.0184$) |
|                                  |        |                |                             |                                     |                             |                                             | Significant in breast cancer Distress (no/yes), emergency costs 13.4% versus 29.4% ($p = 0.0131$) |
|                                  |        |                |                             |                                     |                             |                                             | Significant in breast cancer Distress (no/yes), dental visits costs 59.6% versus 38.0% ($p = 0.0099$) |
|                                  |        |                |                             |                                     |                             |                                             | Not significant in mixed cancer Distress and office-based costs, total expenditures and total costs |
|                                  |        |                |                             |                                     |                             |                                             | Not significant in prostate cancer Distress and hospital outpatient, inpatient, home healthcare and dental |
|                                  |        |                |                             |                                     |                             |                                             | Not significant in colorectal cancer Distress and hospital outpatient, inpatient, home healthcare emergency, medication prescription and total costs |
|                                  |        |                |                             |                                     |                             |                                             | Not significant in breast cancer Distress and office-based costs, hospital outpatient, home healthcare, medication prescriptions and total costs |

Abbreviations: CES-D, Center for Epidemiologic Studies Depression Scale; Diff, difference; ED, emergency department; ER, emergency room; FCR, fear of cancer recurrence; GAD, generalized anxiety disorder; HADS, Hospital Anxiety and Depression Scale; HHC, hepatocellular carcinoma; ICD-9-CM, International Classification of Diseases; K6, Kessler-6; NIS, Nationwide Inpatient Sample; SCID, Structured Clinical Interview for DSM-IV.

<sup>a</sup>Significant results in this column indicate a positive association between psychological problems and costs, unless otherwise specified.

<sup>b</sup>Article is also presented in Tables 1, 2 or 3.
In summary, all studies were published between 1972 and 2020, of which 24 studies were conducted in the United States (19/25) scored negative on the item “patients who want to quality as demonstrated in Appendix B. Most of the studies were performed among mixed cancer patients (N = 20) and breast cancer patients (N = 11). Other studies were performed across a variety of other cancer patients: colorectal (N = 5), prostate cancer (N = 2), lung cancer (N = 3), hepatocellular carcinoma (N = 2), head and neck cancer (N = 2), Gynecologic cancer (N = 1), glioma cancer (N = 1), gastrointestinal cancer (N = 1), hematological malignancy (N = 1) and lymphoma (N = 1) patients. Sample sizes ranged from 42 to 50,147 patients.

Of all 49 studies, 34 studies focused on psychological symptoms, 14 studies focused on psychological symptoms, and one study focused on both. Focusing on psychological symptoms, 10 studies investigated symptoms of anxiety as measured using the Hospital Anxiety and Depression Scale (HADS), General Anxiety Disorder-7, State-Trait Anxiety Inventory (STAI), PROMIS Anxiety or Patient Health Questionnaire-4 (PHQ-4), 20 studies investigated symptoms of depression as measured using the HADS, PHQ-9, Center for Epidemiological Studies Depression Scale, Geriatric Depression Scale, PROMIS, Back Depression Inventory II or a study specific questionnaire, six studies investigated fear of cancer recurrence measured with the Fear of Cancer Recurrence Inventory – Short Form, Concerns About Recurrence Scale or the Fear of Progression Questionnaire-Short Form (FoP-Q-SF), and 11 studies investigated distress measured with the HADS, Impact of Event Scale, Distress Thermometer or Kessler Psychological Distress Scale (K10 and K6).

Of the 14 studies that investigated psychiatric disorders, one study used a psychiatric interview (i.e., The Structured Clinical Interview) to investigate the presence of a depression disorder. In all other studies, the psychiatric disorder was retrieved from medical files: two studies focused on adjustment disorder, three studies on anxiety disorder, 13 studies on depression disorder, and two studies on presence of any psychiatric disorders (i.e., a combination of anxiety disorder and/or depression disorder and/or adjustment disorder).

### 3.2 Quality assessment

Thirty-seven of the 49 studies were of high methodological quality as demonstrated in Appendix B. Most of the studies (19/25) scored negative on the item “patients who want to participate in study (participation rate)” due to a participation rate lower than 80%, a missing baseline participating rate or a selective non-response. Half of the included articles (25/49) did not meet the criteria for sufficient reporting of baseline descriptive, in particular, time since diagnosis, tumor stage, and/or treatment were often not reported. Almost all studies (42/49) used multivariate analyses and included more than 100 patients (47/49).

### 3.3 Psychological problems in relation to healthcare use

Table 5 provides an overview of the results regarding type of psychological problem (i.e., anxiety symptoms, depressive symptoms, distress, fear of cancer recurrence, anxiety disorder, depression disorder, adjustment disorder or any psychiatric disorder) and type of healthcare use (i.e., mental, supportive, nonmental, primary, oncology-related, inpatient, outpatient, and medicine and other healthcare use). Thirty six studies investigated 48 associations in total of which six showed a strong evidence two a moderate evidence and 40 showed inconclusive evidence.

We found strong evidence that a depression disorder was positively associated with increased mental healthcare use. Also, there was strong evidence that fear of cancer recurrence was positively associated with more use of primary care (i.e., GP). In addition, strong evidence was found for a positive association between depression disorder and increased inpatient healthcare use (e.g., hospitalization, inpatient healthcare use and intensive care admission) for nine studies. Moderate evidence (one high and one low quality study) was found for the association between any psychiatric disorder and inpatient care use (e.g., hospitalization, increased length of hospitalization). Moderate evidence was also found for the association between depression disorder and increased medication (i.e., number of prescriptions). Inconclusive evidence was found for many (n = 40) of the studies. Remarkable, however, were the negative associations found with regard to oncology related healthcare and psychological symptoms (i.e., depressive symptoms and fear of cancer recurrence) as these were the only examples of all healthcare use associations, in which studies demonstrated that the psychological symptoms were associated with decreased healthcare use (i.e., oncology-related visits, mammography screening and other screening practices).
| Psychological symptoms | Mental healthcare | Supportive nonmental healthcare | Primary care | Oncology-related healthcare | Inpatient care | Outpatient care |
|------------------------|-------------------|---------------------------------|--------------|-----------------------------|---------------|----------------|
| Anxiety                | + (1) (2) (3)      | + (2)                            | + (4) (3)    | + (2)                       | + (20) ^5     | + (1)          |
| Depression             | - (4) ^1 (2) (3)  | - (2)                            | - (4) ^2 (1) | - (2)                       | - (33) (32)  | - (1)          |
| Distress               | - (5) (6) (3)     | - (1)                            | - (3)        | - (4) ^2 (18) ^21          | - (35) (22)  | - (35) ^7 (22)|
| Fear of cancer recurrence | - (7) (8)        | - (1)                            | - (3)        | - (8)                       | - (15)        | - (15)         |
| Psychiatric disorder   |                   |                                 |              |                             |               |                |
| Adjustment disorder    | - (3)             | - (2)                            | - (3)        | - (16) (18) ^20            | - (23)        | - (23)         |
| Anxiety disorder       | - (9) (3)         | - (1)                            | - (3)        | - (8)                       | - (24) (23)  | - (24) (23)    |
| Depression disorder    |                   |                                 | - (17) (3)  | - (19) ^5 (36) (29) ^18    |               | - (17) (19)    |

Note: LoE: Level of Evidence
| Psychological symptoms | Psychiatric disorder |
|------------------------|----------------------|
| Anxiety | Depression | Distress | Fear of cancer recurrence | Adjustment disorder | Anxiety disorder | Depression disorder | Any psychiatric disorder* |
| LoE | ? | ? | ? | ? | ? | ++ | ++ | ? |
| **Medication** | | | | | | | | |
| N+ | ? | ? | (34) | (22) | (7) (16) | (25) (17) | | |
| N− | | | (15) | | | | | |
| NO | | | (22) | | | | | |
| LoE | ? | ? | ? | ? | | | | |
| **Other healthcare use** | | | | | | | | |
| N+ | ? | ? | (13)12 (22)15 | (16)16 | | | | |
| N− | | | (22)19 | | | | | |
| NO | (3)11 | (3)11 | (3)11 (22)16 | | | | | |
| LoE | ? | ? | ? | ? | ? | ? | ? | |

Note: High-quality studies were printed in bold and underlined. 1, healthcare use before depression diagnosis; 2, healthcare use after depression diagnosis; 5, readmission; 6, ICU admission; 7, hospital length of stay; 8, inpatient admission; 9, a little distress compared to never; 10, sometimes and most times distress compared to never; 11, somatic healthcare use; 12, service use; 13, other service use; 14, phone calls; 15, home healthcare among mixed cancer patients; 16, home healthcare among prostate, colorectal and breast cancer; 17, men; 18, women; 19, dental healthcare among mixed and breast cancer patients; 20, routine follow-up care cancer; 21, healthcare provider visits related to cancer; (1), Keyzer-Dekker; (2), Holla; (3), Compen; (4), Lo; (5), Trevino; (6), Arts; (7), Champagne; (8), Thewes; (9), Jacobsen; (10), Faller; (11), Mosher; (12), Sarkar; (13), Hamilton; (14), Schuurhuizen; (15), Lebet; (16), Otto; (17), Bhattacharj; (18), Vachon; (19), McDermott; (20), Nipp; (21), Oleske; (22), Han X; (23), Jeffer; (24), Mausbach; 2020; (25), Jeffery 2012; (26), Mausbach, 2017; (27), Jayadevappa; (28), Niazi; (29), Laurence; (30), Fox; (31), Lee; (32), Doll; (33), Cagle; (34), Godby; (35), Rana; (36), Pan X.

Abbreviations: LoE, level of evidence; N−, negative association; N+, positive association; NO, no association; +, moderate evidence positive associations; ++, strong evidence positive association; ?, inconclusive or limited evidence on association.

*Combination of anxiety disorder and/or depression disorder and/or adjustment disorder.
3.4 | Psychological problems in relation to economic losses by patients and family

Six studies investigated the association between psychological problems and economic losses by patients and family, namely use of CAM (n = 4), healthcare use by spouses (n = 2) and lost work productivity of spouses (n = 1) (Table 6). Inconclusive evidence was found for all of the 10 investigated associations, of which eight due to the fact that only one study investigated the association. The association between fear of cancer recurrence and CAM use was investigated in three studies of which one study found a positive association with increased number of CAM but no association with use of CAM (yes/no) among breast cancer patients, and two studies found no association at all among a mixed cancer population.

3.5 | Psychological problems in relation to losses in other sectors

Eight studies investigated in total three associations between psychological problems and losses in other sectors, all of them focused on return to work (Table 7). Strong evidence was found that symptoms of anxiety and depression were negatively associated with return to work, indicating that patients with symptoms did not or returned later to work than patients without symptoms or with less symptoms. Three studies found a negative association between anxiety symptoms and return to work at 9, 12 and 24 months after cancer diagnosis among mixed, breast and hematological cancer patients, respectively. Six studies found a negative association between depressive symptoms and return-to-work at 6, 12, 15, 18 and 24 months after diagnosis also among mixed, breast and hematological cancer patients. One study among breast cancer patients compared return-to-work among three groups of patients (no symptoms of depression, moderate symptoms of depression and severe symptoms of depression), which found that patients with severe symptoms of depression did return to work later than patients with low symptoms of depression, whereas no such difference was found in comparison to patients with moderate symptoms of depression. Inconclusive evidence was found on the association between distress and return-to-work among colorectal cancer patients.

3.6 | Psychological problems in relation to losses in monetary units

Thirteen studies investigated 33 associations in total between psychological problems and costs in monetary units (i.e., mental, inpatient, outpatient medicine total healthcare, productivity losses and out of pocket costs) (Table 8). of which four showed a strong association and 29 showed inconclusive evidence. There was strong evidence that a depression disorder was positively associated with inpatient, outpatient and total healthcare costs. Three high quality studies found a positive association between a depression disorder and inpatients costs among mixed cancer patients. Three high-quality studies also found a positive association between depression disorder and outpatient costs among mixed cancer patients, whereas one high quality study found no association among multiple myeloma patients. Six high-quality studies found a positive association between a depression disorder and total healthcare costs among head and neck (N = 1), multiple myeloma (N = 1) and mixed (N = 4) cancer patients. One additional study among prostate cancer patients reported a positive association between post-treatment depression disorder and total healthcare costs in year two and three following diagnosis, whereas no such association was found in the same study with total healthcare costs in the year following diagnosis or year four and five post diagnosis. Furthermore, there was strong evidence that an anxiety disorder was positively associated with total healthcare costs among mixed cancer patients. Inconclusive or limited evidence was found for all 29 other investigated associations.

4 | DISCUSSION

The aim of this systematic review was to investigate associations between psychological problems and healthcare and societal related resource use and costs among cancer patients. In total 49 studies were included in this systematic review which investigated 94 different associations between psychological problems and healthcare or societal resource use or costs: 48 for healthcare use, 10 for economic losses of patients and their family, three on other losses such as return to work and 33 for total costs as measured in monetary units. For 14 of these 94 associations, moderate or strong evidence was found. Fear of cancer recurrence, having an anxiety disorder, having a depression disorder and having any psychiatric disorder were associated with higher healthcare use on at least one healthcare subcategory (i.e., mental, primary, inpatient or outpatient healthcare). Anxiety symptoms and depression symptoms were associated with reduced return to work, presence of an anxiety disorder was associated with higher total healthcare costs; and presence of a depression disorder was associated with higher inpatient, outpatient and total healthcare costs. For all other 80 investigated associations inconclusive evidence was found, mostly due to limited studies or inconsistent evidence.

This study confirms the hypothesis made by Carlson and Bultz that cancer patients with psychological problems may not only have increased mental healthcare use but also make more use of other domains of healthcare. We found strong evidence that fear of cancer recurrence was positively associated with increased primary healthcare use. Inconclusive evidence was found for symptoms of anxiety, symptoms of depression, distress and fear of cancer recurrence in relation to all other healthcare use categories, often due to inconsistent findings. However, strong evidence was found that both anxiety disorder and depression disorder were associated with increased inpatient and outpatient healthcare use. In addition, evidence was found for
### TABLE 6  Factors associated with economic losses by patients and family

| Psychological symptoms       | Fear of cancer recurrence | Psychiatric disorders |
|-----------------------------|---------------------------|-----------------------|
| Anxiety                     | Depression                | Distress              | Adjustment disorder | Anxiety disorder | Depression disorder |
| CAM                         | N+                        | (3)                   | (3)                 | (8)             | (3)               | (3)               |
| N−                          |                           |                       |                     |                 |                   |
| NO                          | (12)                      | (3)                   | (7) (8)             | (12)            | (3)               | (3)               |
| LoE                         | ?                         | ?                     | ?                   | ?               | ?                 |

| Healthcare use of spouses   |                           |                       |                     |                 |                   |
| N+                          | (37)                      | (38)                  |                     |                 |                   |
| N−                          |                           |                       |                     |                 |                   |
| NO                          | (37)                      |                       |                     |                 |                   |
| LoE                         | ?                         | ?                     |                     |                 |                   |

| Lost work productivity of spouses |                           |                       |                     |                 |                   |
| N+                          | (38)                      |                       |                     |                 |                   |
| N−                          |                           |                       |                     |                 |                   |
| NO                          | (38)                      |                       |                     |                 |                   |
| LoE                         | ?                         | ?                     |                     |                 |                   |

Note: High-quality studies were printed in bold and underlined. 1, complementary and alternatively medicine use (number); 2, complementary and alternatively medicine use (yes/no); (3), Compen; (7), Champagne; (8), Thewes; (12), Sarkar; (37), Litzelman; (38), Manne.

Abbreviations: CAM, complementary and alternatively medicine use; LoE, level of evidence; N−, negative association; N+, positive association; N0, no association; ?, inconclusive or limited evidence on association.
an association between depression disorder and increased mental healthcare use and any type of psychiatric disorder (including anxiety and depression disorder) and inpatient care use. This discrepancy in findings between healthcare use and symptoms of anxiety and depression versus anxiety and depression disorder may be caused by a dose-response relationship; that is, anxiety or depression problems may only result in higher healthcare use when the problem exceeds a certain threshold. However, it may also be that the association between symptoms of anxiety or depression and healthcare use only exists in certain groups of cancer patients or with specific healthcare use categories. This might explain why in a previous study among 4,020 mixed cancer patients no associations were found between anxiety and depressive symptoms and increased healthcare use, whereas in another study among 3,957 colorectal cancer patients this association was found to be significant.

In contrast to the hypothesis of Carlson and Bultz, the only healthcare use category which showed evidence (although inconclusive) of a negative association with psychological problems was oncology-related care. So far, five studies have investigated the association between symptoms of depression or fear of cancer recurrence and use of oncology related care of which two studies found lower oncology-related care use among patients with psychological symptoms. In four studies, however, also evidence was also found for no or a positive association (some studies found evidence for both a negative association and absence of an association). An explanation may be that patients with higher symptoms of depression or fear of cancer recurrence have a more avoidant coping style which may limit the uptake of specific types of oncology-related care. Further research is however needed to unravel this association.

With regard to economic losses of patient and family we found inconclusive evidence for all associations, mostly due to limited studies (i.e., eight of the 10 associations were investigated by only one study). Only two studies have investigated the association between psychological problems among breast cancer and mixed cancer patients and healthcare use and productivity losses among their spouses.

With regard to economic losses in other sectors, we found strong evidence that anxiety and depressive symptoms are negatively associated with return-to-work. These results are in line with the hypothesis of Carlson and Bultz that the economic consequences of psychological problems among cancer patients are larger than the economic costs of (mental) healthcare only. In our systematic review, we only included articles which measured return-to-work with insight on time absent from work. Studies that investigated the association but without a clear timeframe for returning to work were excluded as the association between psychological problems and return-to-work in these studies may have been biased by time since diagnosis. Remarkable, however, was that no study included in our systematic review investigated the association between psychiatric disorders and return-to-work. We hypothesize, however, that in line with the results on psychological symptoms and return-to-work, psychiatric disorders are also negatively associated with return to work.
| TABLE B  Factors associated with losses in monetary units |
|---------------------------------------------------------|
| **Psychological symptoms**                              | **Psychiatric disorder** |
| Anxiety | Depression | Distress | Fear of cancer recurrence | Anxiety disorder | Depression disorder | Any psychiatric disorder<sup>a</sup> |
| Mental healthcare | N+ | (3) | (3) | (3) | (3) | (3) |
| | N− | | | | (3) | (3) |
| | N0 | (3) | | (3) | (3) | |
| | LoE | ? | ? | ? | ? | ? |
| Inpatient | N+ | (47) | (22) | | (24) | (48) | (24) | (28) | (31) |
| | N− | | | | | | | | |
| | N0 | (22) | | | | | | | |
| | LoE | ? | ? | ? | ++ | ? |
| Outpatient | N+ | (47) | (22) | | (24) | (36) | (48) | (24) | (31) |
| | N− | | | | | | | | |
| | N0 | (47) | (22) | | | | | | |
| | LoE | ? | ? | ? | ++ | ? |
| Medication | N+ | (22) | | | | (36) | | |
| | N− | | | | | | | |
| | N0 | (47) | (49) | (22) | | | | |
| | LoE | ? | ? | ? | | |
| Total healthcare costs | N+ | (49) | | (23) | (24) | (23) | (36) | (48) | (24) | (27) | (3) | (28) | (25) | (30) |
| | N− | | | | | | | | | | | | |
| | N0 | (22) | | | | | | | | | | | |
| | LoE | ? | ? | ? | ++ | ++ | ? |
| Absenteism/presenteeism (costs) | N+ | (49) | | | | | | |
| | N− | | | | | | | |
| | N0 | ? | | | | | |
| | LoE | | | | | | | | |
| Psychological symptoms | Psychiatric disorder | Any psychiatric disorder |
|------------------------|----------------------|-------------------------|
| Anxiety | Depression | Distress | Fear of cancer recurrence | Adjustment disorder | Anxiety disorder | Depression disorder | |
| Out of pocket costs |  |  |  |  |  |  |  |
| N+ |  |  |  |  |  |  |  |
| N− |  |  |  |  |  |  |  |
| N0 |  |  |  |  |  |  |  |
| LoE |  |  |  |  |  |  |  |
| Other costs |  |  |  |  |  |  |  |
| N+ |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| N− |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| N0 |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| LoE |  |  |  |  |  |  |  |

Note: High-quality studies were printed in bold and underlined. 1, measured with odds ratio's; 2, measured with beta coefficients; 3, among mixed and breast cancer patients; 4, among prostate and colorectal cancer patients; 5, among prostate and colorectal cancer patients; 6, among breast, prostate and colorectal patients; 7, among mixed and prostate cancers; 8, among breast and colorectal; 9, year of costs taking into account differed; 10, somatic and complementary healthcare costs; 11, Medicare and other costs; 12, overall costs; 13, treatment costs; 14, home and dental care costs among mixed cancer patients; 15, dental healthcare costs among colorectal and breast cancer patients; 16, home healthcare costs among colorectal, prostate, and breast cancer patients; 17, dental healthcare costs among prostate cancer patients; 18, dental healthcare costs among mixed cancer patients; 19, Keyzer-Dekker; 20, Holla; 21, Compen; 22, Lo; 23, Trevino; 24, Arts; 25, Champagne; 26, Thewes; 27, Jacobsen; 28, Faller; 29, Mosher; 30, Arts; 31, Sarkar; 32, Hamilton; 33, Schuurhuizen; 34, Lebel; 35, Otto; 36, Bhattacharji; 37, Vachon; 38, McDermott; 39, Nipp; 40, Oleske; 41, Han X.; 42, Jeffery, 2019; 43, Mausbach, 2020; 44, Jeffery, 2012; 45, Jayadevappa; 46, Niazi; 47, Laurence; 48, Fox; 49, Doll; 50, Cagle; 51, Goody; 52, Godby; 53, Rana; 54, Pan X.; 55, Litzelman; 56, Manne; 57, Dumas; 58, Horsboel; 59, Schonfeld; 60, Landeiro; 61, Rosbjerg; 62, Spelten; 63, Schmidt; 64, Den Bakker; 65, Gu; 66, Mausbach 2018; 67, Boele.

Abbreviations: N−, negative association, N+, positive association, N0, no association, LoE, level of evidence; +, moderate evidence positive associations; ++, strong evidence positive association; ?, inconclusive or limited evidence on association.

Combination of anxiety disorder and/or depression disorder and/or adjustment disorder.
With regard to losses in monetary units, strong evidence showed that depression disorder was positively associated with more inpatient care costs, outpatient care costs and total care costs. Anxiety disorder was also found to be positively associated with more inpatient care costs. Evidence on all other 26 associations was limited or inconclusive. Further research is needed to explore these associations and take possible moderators or mediators (e.g., coping style, social support) into account. For example, studies have demonstrated that cancer patients with psychological problems are more likely to develop comorbidities and are less likely to adhere to cancer treatment or lifestyle recommendations which may result in higher costs. However, comorbidities may also lead to more psychological problems. The pathway via which psychological problems affect healthcare and societal resource use and costs, or the reverse, is thus not yet completely understood. Further research is needed on third variables such as coping style, and social support.

5 | STUDY LIMITATIONS

A strength of this study is that it focused on different psychological symptoms and disorders as well as different types of healthcare and societal costs. Also, in contrast to a previous systematic review, the methodological quality of the included studies was investigated. Furthermore, we used the Dutch guidelines to define economic outcome categories. However, we acknowledge that this framework may not be suitable for all countries, as in some countries, for example, the healthcare costs are paid directly by the patient (without insurance). In those countries healthcare resource use may need to be categorized as "economic losses by patients and their family" instead of the category on "healthcare use." A limitation is that vote counting was used to summarize the findings of the included studies. The absence of an association in some of the included studies may have been the consequence of limited power rather than an actual absence of an association. Meta-analyses can solve this problem. However, we did not perform meta-analyses, as studies were very heterogeneous in study population, psychological problem, cost category investigated, as well as measurements instruments. Our aim was to provide an overview on all economic consequences investigated in relation to psychological problems among cancer patients and a summarized direction of an association instead of the magnitude of the association. Finally, a limitation of this study is that based on the included studies we cannot draw conclusions on the causality of psychological problems and healthcare, societal resource use and costs among cancer patients as almost all studies had a cross-sectional design.

6 | CLINICAL IMPLICATIONS

Results of this systematic review indicate that the economic consequences of psychological problems among cancer patients are beyond mental healthcare costs only. Psychological problems among cancer patients also impact societal costs such as losses due to delayed return to work. This information is important to consider when building a business case for the reimbursement of psychological treatment for cancer patients. Based on the results of this systematic review we claim that treating psychological problems in general among cancer patients may not only improve psychological well-being among cancer patients but also lead to medical cost offset and improved return-to-work. Two previous reviews and later published studies showed evidence that psychological treatment for patients with cancer is not only effective, but may also be cost saving. Several other studies are ongoing, including one study on the effectiveness, cost-utility and budget impact of psychological treatment among cancer patients with an adjustment disorder, which, as also shown in this systematic review, is still an understudied population.

7 | CONCLUSIONS

Psychological problems in cancer patients are associated with increased healthcare use, healthcare costs and economic losses, especially for (symptoms of) anxiety and depression disorder, and fear of cancer recurrence. Future research is needed on psychological problems in relation to understudied healthcare use or costs categories, productivity losses of patients and their caregivers, and informal care costs.

ACKNOWLEDGEMENTS
This research was funded by a ZonMw, The Netherlands Organisation for Health (grant number: 856001005). The funding source had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.

CONFLICT OF INTEREST
All authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS
F. E. Van Beek: conceptualization; methodology; investigation; writing Original Draft. L. M. A. Wijnhoven: conceptualization; investigation; writing - Review Editing. Karen Holtmaat: writing - Review Editing. José A. E. Custers: writing - Review Editing. Judith B. Prins: writing - Review Editing. Irma M. Verdonck-de Leeuw: conceptualization; writing - Review Editing; supervision; funding Acquisition. F. Jansen: conceptualization; methodology; investigation; writing - Review Editing; supervision.

DATA AVAILABILITY STATEMENT
The data that support the findings of this systematic review are all presented in Tables 1-4.

ORCID
Lonneke M. A. Wijnhoven https://orcid.org/0000-0002-4234-4704
Karen Holtmaat https://orcid.org/0000-0002-1067-3327
REFERENCES

1. Krebber A, Buffart L, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. *Psychooncology*. 2014;23:121-130.

2. Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. *J Cancer Surviv*. 2013;7:300-322.

3. Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. *Lancet Oncol*. 2013;14:721-732.

4. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. *Lancet Oncol*. 2011;12:160-174.

5. Dunne S, Mooney O, Coffey L, et al. Psychological variables associated with quality of life following primary treatment for head and neck cancer: a systematic review of the literature from 2004 to 2015. *Psychooncology*. 2017;26:149-160.

6. Carlson LE, Bulz TD. Efficacy and medical cost offset of psychosocial interventions in cancer care: making the case for economic analyses. *Psychooncology*. 2004;13:837-849.

7. Jack K, McLean SM, Moffett JK, Gardiner E. Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. *Man Ther*. 2010;15:220-228.

8. Proctor EK, Morrow-Howell NL, Doré P, et al. Comorbid medical conditions among depressed elderly patients discharged home after acute psychiatric care. *Am J Geriatr Psychiatry*. 2003;11:329-338.

9. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? *Diabetes Care*. 2000;23:1556-1562.

10. Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. The effects of chronic medical conditions on work loss and work cutback. *J Occup Environ Med*. 2001;43:218-225.

11. Stewart WF, Ricci JA, Chee E, Hahn SR, Morgenstein D. Cost of lost productive work time among US workers with depression. *JAMA*. 2003;289:3135-3144.

12. de Oliveira C, Weir S, Rangrej J, et al. The economic burden of cancer care in Canada: a population-based cost study. *CMAJ Open*. 2018;6:E1-E10.

13. Khushalani JS, Qin J, Cyrus J, et al. Systematic review of healthcare costs related to mental health conditions among cancer survivors. *Expert Rev Pharmacoecon Outcomes Res*. 2018;18:505-517.

14. Duijts SF, Van Egmond MP, Spelten E, Van Muijen P, Anema JR, van der Beek AJ. Physical and psychosocial problems in cancer survivors beyond return to work: a systematic review. *Psychooncology*. 2014;23:481-492.

15. Islam T, Dahlui M, Abd Majid H, et al., eds. Factors associated with return to work of breast cancer survivors: a systematic review. *BMC Public Health*. 2014;14 Suppl 3:58.

16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PloS Med*. 2009;6:e1000097.

17. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. *Ann Intern Med*. 2006;144:427-437.

18. Drummond M, Agüiar-IBanez R, Nixon J. Economic evaluation. *Singap Med J*. 2006;47:456.

19. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford University Press; 2015.

20. Korsten LH, Jansen F, de Haan BJ, et al. Factors associated with depression over time in head and neck cancer patients: a systematic review. *Psychooncology*. 2019;28:1159-1183.

21. Kampshoff CS, Jansen F, van Mechelen W, et al. Determinants of exercise adherence and maintenance among cancer survivors: a systematic review. *Int J Behav Nutr Phys Act*. 2014;11:80.

22. Zorginstituut N. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Zorginstituut Nederland; 2015.

23. Uijtdewilligen L, Nauta J, Singh AS, et al. Determinants of physical activity and sedentary behaviour in young people: a review and quality synthesis of prospective studies. *Br J Sports Med*. 2011;45:896-905.

24. Arts LP, Oerlemans S, Fransve L. More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: results from the population-based PROFILES registry. *Cancer*. 2018;124:3016-3024.

25. Bhattacharai N, Charlton J, Rudisill C, Guilford MC. Prevalence of depression and utilization of health care in single and multiple morbidity: a population-based cohort study. *Psychol Med*. 2013;43:1423-1431.

26. Boele FW, Meads D, Jansen F, et al. Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms. *J Neurooncol*. 2020;147:1-10.

27. Cagle JG, Lee J, Ornstein KA, Guralnik JM. Hospice utilization in the United States: a prospective cohort study comparing cancer and noncancer deaths. *J Am Geriatr Soc*. 2020;68:783-793.

28. Champagne A, Ivers H, Savard J. Utilization of health care services in cancer patients with elevated fear of cancer recurrence. *Psychooncology*. 2018;27:1958-1964.

29. Compen F, Adang E, Bisseling E, Van der Lee M, Speckens A. Exploring associations between psychiatric disorder, psychological distress, and health care utilization in cancer patients. *Psychooncology*. 2018;27:871-878.

30. Den Bakker C, Anema J, Huirne J, Twisk J, Bonjer H, Schaafsm A. Predicting return to work among patients with colorectal cancer. *Br J Surg*. 2020;107:140.

31. Doll KM, Barber EL, Bensen JT, Snayevly AC, Gehrig PA. The health-related quality of life journey of gynecologic oncology surgical patients: implications for the incorporation of patient-reported outcomes into surgical quality metrics. *Gynecol Oncol*. 2016;141:329-335.

32. Dumas A, Luis IV, Bovagnet T, et al. Impact of breast cancer treatment on employment: results of a multicenter prospective cohort study (CANTO). *J Clin Oncol*. 2020;38:734-743.

33. Faller H, Weis J, Koch U, et al. Utilization of professional psychological care in a large German sample of cancer patients. *Psychooncology*. 2017;26:537-543.

34. Fox JP, Philip EJ, Gross CP, Desai RA, Killelea B, Desai MM. Associations between mental health and surgical outcomes among women undergoing mastectomy for cancer. *Breast*. 2013;19:276-284.

35. Godby RC, Dai C, Al-Obaidi M, et al. Depression among older adults with gastrointestinal malignancies. *J Geriatr Oncol*. 2020;12:599-604.
36. Gu D, Morgan RO, Li R, Weber ES, Shen C. Association between depression and healthcare expenditures among elderly cancer patients. BMC Psychiatr. 2020;20:1-10.
37. Hamilton J, Kroska EB. Distress predicts utilization of psychosocial health services in oncology patients. Psychooncology. 2019;28:61-67.
38. Han X, Lin CC, Li C, et al. Association between serious psychological distress and health care use and expenditures by cancer patients. Cancer. 2015;121:614-622.
39. Holla JF, van de Poll-Franse LV, Huigens PC, Mols F, Dekker J. Utilization of supportive care by survivors of colorectal cancer: results from the PROFILES registry. Support Care Cancer. 2016;24:2883-2892.
40. Horsboel TA, Bültmann U, Nielsen CV, Nielsen B, Andersen NT, de Thurah A. Are fatigue, depression and anxiety associated with labour market participation among patients diagnosed with haematological malignancies? A prospective study. Psychooncology. 2015;24:408-415.
41. Jacobsen JC, Zhang B, Block SD, Maciejewski PK, Priegerson HG. Distinguishing symptoms of grief and depression in a cohort of advanced cancer patients. Death Stud. 2010;34:257-273.
42. Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ. The impact of depression as a cancer comorbidity: rates, health care utilization, and associated costs. Can Fam Physician. 2013;60:1834-1841.
43. Jeffery DD, Art Ambrosio L, Hopkins L, Burke HB. Mental health comorbidities and cost/utilization outcomes in head and neck cancer patients. J Psychosoc Oncol. 2019;37:301-318.
44. Jeffery DD, Linton A. The impact of depression as a cancer comorbidity: rates, health care utilization, and associated costs. Community Oncol. 2012;7:216-221.
45. Keyzer-Dekker CM, Van Esch L, Schreurs WH, et al. Health care utilization one year following the diagnosis benign breast disease or breast cancer. Breast. 2012;21:746-750.
46. Laurence B, Mould-Millman NK, Nero KE, Jr, Salter RO, Sagoo PK. Depression and hospital admission in older patients with head and neck cancer: analysis of a national healthcare database. Gerodontology. 2017;34:284-287.
47. Lebel S, Tomei C, Feldstain A, Beattie S, McCallum M. Does fear of cancer recurrence predict cancer survivors’ health care use? Support Care Cancer. 2013;21:901-906.
48. Lee K-T, Lin J-J, Shi H-Y. Anxiety and depression are associated with long-term outcomes of hepatocellular carcinoma: a nationwide study of a cohort from Taiwan. World J Biol Psychiatry. 2018;19:431-439.
49. Landeiro LC, Gagliato DM, Fé de AB, et al. Return to work after breast cancer diagnosis: an observational prospective study in Brazil. Cancer. 2018;124:4700-4710.
50. Litzelman K, Choi H, Maher ME, Harnish A. Role of cancer survivor health and health service use in spouses’ use of mental health-related care. Cancer. 2020;127:1146-1153.
51. Lo C, Calzavara A, Kurydyak P, et al. Depression and use of health care services in patients with advanced cancer. Can Fam Physician. 2013;59:166-e174.
52. Manne SL, Siegel S, Heckman CJ, Kashy DA. Psychological distress as a mediator of the association between disease severity and occupational functioning among employed spouses of women recently diagnosed with breast cancer. Psychooncology. 2015;24:1560-1568.
53. Mausbach BT, Decastro G, Schwab RB, Tiamson-Kassab M, Irwin SA. Healthcare use and costs in adult cancer patients with anxiety and depression. Depress Anxiety. 2020;37:908-915.
54. Mausbach BT, Irwin SA. Depression and healthcare service utilization in patients with cancer. Psychooncology. 2017;26:1133-1139.
55. Mausbach BT, Yeung P, Bos T, Irwin SA. Health care costs of depression in patients diagnosed with cancer. Psychooncology. 2018;27:1735-1741.
56. McDermott CL, Bansal A, Ramsey SD, Lyman GH, Sullivan SD. Depression and health care utilization at end of life among older adults with advanced non-small-cell lung cancer. J Pain Symptom Manage. 2018;56:699-708.e1.
57. Niazi S, Frank RD, Sharma M, et al. Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Adv. 2018;2:1120-1128.
58. Nipp RD, El-Jawahir A, Moran SM, et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer. 2017;123:4720-4727.
59. Oleske DM, Cobleigh MA, Phillips M, Nachman KL, eds. Determination of factors associated with hospitalization in breast cancer survivors. Oncol Nurs Forum. 2004;31:1081-1088.
60. Otto AK, Soriano EC, Siegel SD, LoSavio ST, Laurenceau J-P. Assessing the relationship between fear of cancer recurrence and health care utilization in early-stage breast cancer survivors. J Cancer Surviv. 2018;12:775-785.
61. Pan X, Sambamoorthi U. Health care expenditures associated with depression in adults with cancer. J Community Support Oncol. 2015;13:240-247.
62. Rana RH, Alam K, Gow J, Ralph N. Predictors of health care use in Australian cancer patients. Canc Manag Res. 2019;11:6941-6957.
63. Rosbjerg R, Hansen DG, Zachariae R, Hoejris I, Lund T, Labriola M. The predictive value of return to work self-efficacy for return to work among employees with cancer undergoing chemotherapy. J Occup Rehabil. 2020;30:665-678.
64. Sarkar S, Sautier L, Schilling G, Bokemeyer C, Koch U, Mehner A. Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients. J Cancer Surviv. 2015;9:567-575.
65. Schmidt ME, Scherer S, Wiskemann J, Steindorf K. Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care. 2019;28:e13051.
66. Schonfeld J. Psychological factors related to delayed return to an earlier life-style in successfully treated cancer patients. J Psychosom Res. 1972;16:41-46.
67. Schuurhuizen CS, Braaams AM, Konings IR, Verheul HM, Dekker J. Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment. BMC Cancer. 2019;19:115.
68. Spelten E, Verbeek J, Uitterhoeve A, et al. Cancer, fatigue and the potential impact on quality of life. Eur J Cancer Care. 2003;12:1562-1567.
69. Thewes B, Butow P, Bell ML, et al. Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours. Support Care Cancer. 2012;20:2651-2659.
70. Trevino KM, Nelson CJ, Saracino RM, Korc-Grodzicki B, Sarraf S, Shahroki A. Is screening for psychosocial risk factors associated with mental health care in older adults with cancer undergoing surgery? Cancer. 2020;126:602-610.
71. Vachon E, Krueger E, Champion VL, Haggstrom DA, Cella D, Cohee AA. The impact of fear of cancer recurrence on healthcare utilization among long-term breast cancer survivors recruited through ECOG-ACRIN trials. Psychooncology. 2021;30:279-286.
72. Mosher CE, Hanna N, Jalal SI, et al. Support service use and interest in support services among lung cancer patients. Lung Canc. 2013;82:162-167.
73. Morris N, Moghaddam N, Tickle A, Biswas S. The relationship between coping style and psychological distress in people with head and neck cancer: a systematic review. Psychooncology. 2018;27:734-747.
74. Verdonck-de Leeuw IM, van Bleek W-J, Leemans CR, de Bree R. Employment and return to work in head and neck cancer survivors. Oral Oncol. 2010;46:56-60.
75. So N, McDowell LJ, Lu L, et al. The prevalence and determinants of return to work in nasopharyngeal carcinoma survivors. Int J Radiat Oncol Biol Phys. 2020;106:134-145.
76. Razavi D, Delvaux N, Bredart A, et al. Professional rehabilitation of lymphoma patients: a study of psychosocial factors associated with return to work. Support Care Cancer. 1993;1:276-278.
77. Jansen F, van Zwieten V, Coupé VM, Leemans CR, Verdonck-de Leeuw IM. A review on cost-effectiveness and cost-utility of psychosocial care in cancer patients. Asia-Pacific J Oncol Nurs. 2016;3:125.
78. Dieng M, Cust AE, Kasparian NA, Mann GJ, Morton RL. Economic evaluations of psychosocial interventions in cancer: a systematic review. Psychooncology. 2016;25:1380-1392.
79. van der Spek N, Vos J, van Uden-Kraan CF, et al. Efficacy of meaning-centered group psychotherapy for cancer survivors: a randomized controlled trial. Psychol Med. 2017;47:1990-2001.
80. Jansen F, Krebber AM, Coupé VM, et al. Cost-utility of stepped care targeting psychological distress in patients with head and neck or lung cancer. J Clin Oncol. 2017;35:314-324.
81. Burm R, Thewes B, Rodwell L, et al. Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal cancer survivors: follow-up of the SWORD randomized controlled trial. BMC Canc. 2019;19:1-13.
82. Klaver K, Duijts S, Geusgens C, et al. Internet-based cognitive rehabilitation for WORking Cancer survivors (i-WORC): study protocol of a randomized controlled trial. Trials. 2020;21:664.
83. Subnis UB, Farb NA, Piedalue K-AL, et al. A smartphone app-based mindfulness intervention for cancer survivors: protocol for a randomized controlled trial. JMIR Res Protoc. 2020;9:e15178.
84. Van Beek FE, Wijnhoven LM, Jansen F, et al. Prevalence of adjustment disorder among cancer patients, and the reach, effectiveness, cost-utility and budget impact of tailored psychological treatment: study protocol of a randomized controlled trial. BMC Psychol. 2019;7:89.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Van Beek FE, Wijnhoven LMA, Holtmaat K, et al. Psychological problems among cancer patients in relation to healthcare and societal costs: a systematic review. Psychooncology. 2021;30(11):1801-1835. https://doi.org/10.1002/pon.5753